ࡱ> q`0bjbjqPqP ::߈d  '8,Dp04Vh("$hh^+9 "+ dݙݙݙZ 8 ݙݙݙ1  \ cBI >Iz0St| ݙtf++Ǚ040404Q040404      Registration Department Jordan Food & Drug administration Explanatory Guidance regarding CTD Submission (For Registration of Pharmaceuticals): Version 1.0 Issue date 6/3/2011 Introduction: -The CTD (Common Technical Dossier) provides a format for the submission of information to regulatory authorities, it does not define content, please refer to the Registration criteria for specific requirements (ex: Bioequivalence, stability, Pharmacovigilance...) so these guidance are not intended to indicate what studies are required. - The required data for each application will differ, depending on the drug submission type, However, all the required data should be in accordance with the CTD structure. - The check list (F1/RDP-3/2011) outlines the CTD Modules required for the submission of: Originator drug , New drug , Biological & Biosimilar drugs. Generic Drugs, Radiopharmaceuticals - This document prepared to guide the applicants when preparing their applications for registration. Detailed explanation of the CTD modules: Module 1: Administrative Data & certificates. This module contains the specific local requirements for the administrative data (e.g. the application form, the proposed summary of product characteristics, labeling and package leaflet, etc.). Application forms (should be signed & stamped from the applicant or from the marketing authorization holder)(should be filled in print and not handwrittenB1'!) 5H*J) DDCDE'*.) Application forms are available on website  HYPERLINK "http://www.JFDA.jo" www.JFDA.jo For the information about: Pharmacovigilance System: Detailed description of the Pharmacovigilance system must be provided this should include proof that the applicant has the services of a qualified person responsible for Pharmacovigilance and the necessary means for the notification of any adverse reaction. Risk-management System (plan). A detailed description of the risk management system which the applicant will introduce should be provided, where appropriate. For the Specific Requirements of Different Types of Applications: Information for application type: If it's Originator it should be specified & if Generic , Biosimilar..details on the medicinal product, its active substance, pharmaceutical form, strengths, therapeutic indications, route of administration as appropriate in comparison to the reference medicinal product should be specified. Information for submission type: (Technology Transfer, under license, contract ..) Applicant Should give information about drug product that are manufactured contractually, or under license, or technology transfer & documents according to registration criteria for each type should be submitted.  Module 2:Common Technical Document Summaries Contains summaries (the Quality Overall Summary, the Non-clinical Overview / Summaries, and the Clinical Overview / Summaries) . Should include sufficient information from each module to provide the reviewer with an overview of all the CTD Modules & should also emphasis critical key parameters of the product and provide, for instance, justification in cases where guidelines were not followed. Module 2.2 Introduction: Should include its pharmacological class, mode of action and the proposed clinical use . Module 2.3 Quality Overall Summary: The following points should be taken into considerations: The Quality Overall Summary (QOS) is a summary that follows the scope and the outline of the Body of Data in Module 3. JFDA Stability Report Form ( F5/RDP-7\2008 ) should be included . The QOS should not include information, data or justification that was not already included in Module 3 or in other parts of the CTD. The QOS should include sufficient information from each section to provide the Quality reviewer with an overview of Module 3, the QOS should also emphasis critical key parameters of the product and provide, for instance, justification in cases where guidelines were not followed. For Generics: Sections Required only: 2.3 Quality Overall Summaries (only JFDA Stability Report Form ( F5/RDP-7\2008 ) should be included) & 2.5 Clinical Overview (the written summary (BE report or Synopsis ) of the bioequivalence has to be part of the Clinical Overview . (Non-clinical and Clinical Summaries can be provided , but they are only mandatory if new additional studies have been provided within the documentation.) Module 2.4 Nonclinical Overview: The interpretation of the data, the clinical relevance of the findings, cross-linking with the quality aspects of the pharmaceutical, and the implications of the nonclinical findings for the safe use of the pharmaceutical (i.e., as applicable to labeling) should be addressed in the Nonclinical Overview. Module 2.5 Clinical Overview: The Clinical Overview is intended to provide a critical analysis of the clinical data in the Common Technical Document, it will necessarily refer to application data provided in the comprehensive Clinical Summary ,the Clinical Overview should provide a succinct discussion and interpretation of these studies together with any other relevant information. Module 2.6 Nonclinical Summary The primary purpose of the Nonclinical Written and Tabulated Summaries should be to provide a comprehensive, factual synopsis of the nonclinical data. Module 2.7 Clinical Summary The Clinical Summary should provide a detailed factual summarisation of the clinical information in the CTD. Module 3: Quality. 3.2 Body of Data 3.2.S DRUG SUBSTANCE The information on the drug substance can be submitted in the following order: Valid European Certificate of Suitability (CEP) with all appendices (copy) for drug substance manufacturer/s. The Drug Substance sections should refer to the Certificate of Suitability in the relevant sections in Module 3.2.S ,the Certificates of Suitability are deemed to replace the data of the corresponding sections(S.2.2 , S.2.3, S.2.4 and S.2.6) and therefore in principle no further additional information is necessary except concerning technical characteristics of the substance where not covered by the Certificate of Suitability (e.g. when the Certificate of Suitability does not describe a specific technical grade, information and data for the re-test period). If the Certificate of Suitability (CEP) is not available all the Drug Substance sections in Module 3.2.S should be full-filled & a valid copy of GMP certificate (for drug substance manufacturer/s) should be included. The information from the Open Part of the DMF should be provided in drug application. Information in sections (S.2.2 , S.2.3, S.2.4 and S.2.6 ) may not be available to the holder of the drug product, they will be in the closed part of the DMF which will be available from the drug substance supplier ,so the supplier of the drug substance can send a Drug Master File (closed part of the DMF) directly to authority . *COS or CEP: Certificate Of Suitability: A Certificate issued from EDQM (European Directorate for the Quality of Medicine) to demonstrate the compliance of the substance used with the monograph of the European Pharmacopoeia.(not issued for biological) GMP certificate: issued from health authorities, the firm follow GMP, should mention the name of drug substance. DMF: drug master file. 3.2.S.1 General Information (name of the active ingredient, manufacturer) Information on the nomenclature of the drug substance (INN), chemical name ,USAN.), Structure (structural formula, molecular formula..). General properties: A list should be provided of physicochemical and other relevant properties of the drug substance, including biological activity for biotech, should be specified. For Biotech: The schematic amino acid sequence indicating glycosylation sites or other posttranslational modifications and relative molecular mass should be provided, as appropriate. 3.2.S.2 Manufacture (name of the active ingredient, manufacturer) 3.2.S.2.1 Manufacture name , address. The name, address, and responsibility of each manufacturer should be provided. Name should comply with (CEP or GMP certificate provided). 3.2.S.2.2 Description of Manufacturing Process& process controls . The description of the drug substance manufacturing process represents the applicants commitment for the manufacture of the drug substance. Information should be provided to adequately describe the manufacturing process (flow diagram) and process controls. For Biotech: Information should be provided on the manufacturing process, which typically starts with a vial(s) of the cell bank, and includes cell culture, harvest(s), purification and modification reactions, filling, storage and shipping conditions. Batch (es) and scale definition: An explanation of the batch numbering system, including information regarding any pooling of harvests or intermediates and batch size or scale should be provided. Cell culture and harvest: A flow diagram should be provided that illustrates the manufacturing route from the original inoculums (e.g. cells contained in one or more vials(s) of the Working Cell Bank up to the last harvesting operation. The diagram should include all steps (i.e., unit operations) and intermediates. Relevant information for each stage, such as population doubling levels, cell concentration, volumes, pH, cultivation times, holding times, and temperature, should be included. Critical steps and critical intermediates for which specifications are established (as mentioned in 3.2.S.2.4) should be identified. A description of each process step in the flow diagram should be provided , information should be included on, for example, scale; culture media and other additives (details provided in 3.2.S.2.3); major equipment (details provided in 3.2.A.1); and process controls, including in-process tests and operational parameters, process steps, equipment and intermediates with acceptance criteria (details provided in 3.2.S.2.4). Information on procedures used to transfer material between steps, equipment, areas, and buildings, as appropriate, and shipping and storage conditions should be provided. (Details on shipping and storage provided in 3.2.S.2.4.) Purification and modification reactions A flow diagram should be provided that illustrates the purification steps (i.e., unit operations) from the crude harvest(s) up to the step preceding filling of the drug substance. All steps and intermediates and relevant information for each stage (e.g., volumes, pH, critical processing time, holding times, temperatures and elution profiles and selection of fraction, storage of intermediate, if applicable) should be included. Critical steps for which specifications are established as mentioned in 3.2.S.2.4 should be identified. A description of each process step (as identified in the flow diagram) should be provided. The description should include information on, for example, scale, buffers and other reagents (details provided in 3.2.S.2.3, major equipment (details provided in 3.2.A.1), and materials. For materials such as membranes and chromatography resins, information for conditions of use and reuse also should be provided. (Equipment details in 3.2.A.1; validation studies for the reuse and regeneration of columns and membranes in 3.2.S.2.5.) The description should include process controls (including in-process tests and operational parameters) with acceptance criteria for process steps, equipment and intermediates. (Details in 3.2.S.2.4.). Reprocessing procedures with criteria for reprocessing of any intermediate or the drug substance should be described. (Details should be given in 3.2.S.2.5.). Information on procedures used to transfer material between steps, equipment, areas, and buildings, as appropriate, and shipping and storage conditions should be provided (details on shipping and storage provided in 3.2.S.2.4.). Filling, storage and transportation (shipping) A description of the filling procedure for the drug substance, process controls (including in-process tests and operational parameters), and acceptance criteria should be provided. (Details in 3.2.S.2.4.) The container closure system(s) used for storage of the drug substance (details in 3.2.S.6.) and storage and shipping conditions for the drug substance should be described. 3.2.S.2.3 Control of Materials. Materials used in the manufacture of the drug substance (e.g., raw materials, starting materials, solvents, reagents, catalysts) should be listed identifying where each material is used in the process. Information on the quality and control of these materials should be provided. For Biotech: Control of Source and Starting Materials of Biological Origin Source, history, and generation of the cell substrate Cell banking system, characterization , and testing 3.2.S.2.4 Control of Critical Steps& intermediates. Critical Steps: Tests and acceptance criteria (with justification including experimental data) performed at critical steps identified in 3.2.S.2.2 of the manufacturing process to ensure that the process is controlled should be provided. Intermediates: Information on the quality and control of intermediates isolated during the process should be provided. 3.2.S.2.5 Process Validation Process validation and/or evaluation studies for aseptic processing and sterilization should be included. For Biotech: Sufficient information should be provided on validation and evaluation studies to demonstrate that the manufacturing process (including reprocessing steps) is suitable for its intended purpose and to substantiate selection of critical process controls (operational parameters and in-process tests) and their limits for critical manufacturing steps (e.g., cell culture, harvesting, purification, and modification). The plan for conducting the study should be described and the results, analysis and conclusions from the executed study(ies) should be provided. The analytical procedures and corresponding validation should be cross-referenced (e.g., 3.2.S.2.4, 3.2.S.4.3) or provided as part of justifying the selection of critical process controls and acceptance criteria 3.2.S.2.6 Manufacturing Process Development. A description and discussion should be provided of the significant changes made to the manufacturing process and/or manufacturing site of the drug substance used in producing nonclinical, clinical, scale-up, pilot, and, if available, production scale batches. For Biotech: The description of change(s) made to the manufacture of drug substance batches used in support of the marketing application (e.g., nonclinical or clinical studies) should include. Testing used to assess the impact of manufacturing changes on the drug substance(s) and the corresponding drug product(s) can also include nonclinical and clinical studies. Cross-reference to the location of these studies in other modules of the submission should be included. 3.2.S.3 Characterization (name of the active ingredient, manufacturer) 3.2.S.3.1 Elucidation of Structure and other Characteristics. Confirmation of structure based on e.g., synthetic route and spectral analyses should be provided. Information such as the potential for isomerism, the identification of stereochemistry, or the potential for forming polymorphs should also be included. For Biotech: For desired product and product-related substances, details should be provided on primary, secondary and higher-order structure, post-translational forms (e.g., glycoforms), biological activity, purity, and immunochemical properties, when relevant. 3.2.S.3.2 Impurities. Specify impurity profile. 3.2.S.4 Control of Drug Substance(name of the active ingredient, manufacturer): 3.2.S.4.1 Specification (name, manufacturer) The specification for the drug substance should be provided. ( if pharmacopoeial a copy of the monograph should be included). 3.2.S.4.2 Analytical Procedures (name, manufacturer) The analytical procedures used for testing the drug substance should be provided. 3.2.S.4.3 Validation of Analytical Procedures (name, manufacturer) Analytical validation information, including experimental data for the analytical procedures used for testing the drug substance, should be provided. Verification used for Pharmacopoeial methods. Validation used for Non- Pharmacopoeial methods. 3.2.S.4.4 Batch Analyses (name, manufacturer) Description of batches and results of batch analyses should be provided. 3.2.S.4.5 Justification of Specification (name, manufacturer) Justification for the drug substance specification should be provided. ( if pharmacopoeial a copy of the monograph should be included). 3.2.S.5 Reference Standards or Materials(name of the active ingredient, manufacturer) Standard name and its manufacturer (provide COA of API reference standard). 3.2.S.6 Container Closure System (name of the active ingredient, manufacturer) Mention the type of the container, closure. 3.2.S.7 Stability (name of the active ingredient, manufacturer) Results of the stability studies (e.g., forced degradation studies and stress conditions) should be presented in an appropriate format such as tabular, graphical, or narrative. Conclusions with respect to storage conditions and retest date or shelf-life, as appropriate. Include stability data minimum of: 6 months at accelerated conditions and 12 months at long term conditions for three batches. 3.2.P DRUG PRODUCT (NAME OF THE FINISHED PRODUCT, DOSAGE FORM) 3.2.P.1 Description and Composition of the Drug Product (name of the finished product, dosage form) A description of the drug product and its composition should be provided. List of all components of the dosage form, and their amount on a per-unit basis (including overages, if any) the function of the components, and a reference to their quality standards (e.g. compendia monographs or manufacturers specifications) NAMES OF INGREDIENTSUNIT FORMULA Percentage formulaFUNCTIONREFERENCE TO STANDARDSACTIVE SUBSTANCEEXCIPIENTS 3.2.P.2 Pharmaceutical Development(name of the finished product, dosage form) This section should contain information on the development studies conducted to establish the dosage form, the formulation, manufacturing process, container closure system, microbiological attribute, usage instructions. 3.2.P.2.1 Components of the Drug Product (name of the finished product, dosage form) 3.2.P.2.1.1 Drug Substance (name of the finished product, dosage form) The compatibility of the drug substance with Excipients should be justified. Physicochemical characteristics for Drug Substance that can influence the performance of the drug product should be discussed (e.g., water content, solubility, particle size distribution or polymorphic form). 3.2.P.2.1.2 Excipients (name of the finished product, dosage form) The functions of Excipients, their concentration and their characteristics that can influence the drug product performance should be discussed for each Excipient. 3.2.P.2.2 Drug Product (name of the finished product, dosage form): 3.2.P.2.2.1 Formulation Development (name of the finished product, dosage form) A brief summary describing the development of the drug product, Including pre formulation studies or justification if not needed. 3.2.P.2.2.2 Overages (name of the finished product, dosage form) Any overages in the formulation should be justified. 3.2.P.2.2.3 Physicochemical and Biological Properties (name of the finished product, dosage form) Parameters relevant to the performance of the drug product, such as pH, ionic strength, dissolution, redispersion, reconstitution, particle size distribution, aggregation, polymorphism, rheological properties, biological activity or potency, and/or immunological activity, to be addressed if needed. 3.2.P.2.3 Manufacturing Process Development (name of the finished product, dosage form) - Specify the critical steps of Manufacturing - Any differences between pivotal clinical batches and the production batches should be mentioned with its justification (ex: scaling up from pilot to production). 3.2.P.2.4 Container Closure System (name of the finished product, dosage form) The suitability of the container closure system (described in 3.2.P.7) used for the storage, transportation (shipping) and use of the drug product should be discussed. e.g., choice of materials, protection from moisture and light, compatibility of the materials of construction with the dosage form (including sorption to container and leaching) safety of materials of construction, and performance (such as reproducibility of the dose delivery from the device when presented as part of the drug product). 3.2.P.2.5 Microbiological Attributes (name of the finished product, dosage form) Where appropriate, the microbiological attributes of the dosage form should be discussed, including, for example, the rationale for not performing microbial limits testing for non sterile products and the selection and effectiveness of preservative systems in products containing antimicrobial preservatives. For sterile products, the integrity of the container closure system to prevent microbial contamination should be addressed. 3.2.P.2.6 Compatibility (name of the finished product, dosage form) The compatibility of the drug product with: - The reconstitution diluent(s) or - Dosage devices (e.g., precipitation of drug substance in solution, sorption on injection vessels, stability) 3.2.P.3 Manufacture (name of the finished product, dosage form) 3.2.P.3.1 Manufacturer(s) (name of the finished product, dosage form) The name, address, and responsibility of Finished product manufacturer, including contractors, and each proposed production site or facility involved in manufacturing and testing should be provided. 3.2.P.3.2 Batch Formula (name of the finished product, dosage form) A batch formula should be provided that includes a list of all components of the dosage form to be used in the manufacturing process and their amounts on a per batch basis. 3.2.P.3.3 Description of Manufacturing Process and Process Controls (name, dosage form) A flow diagram should be presented giving the steps of the process and showing where materials enter the process. The critical steps and points at which process controls, intermediate tests or final product controls are conducted should be identified. A narrative description of the manufacturing process, including packaging, that represents the sequence of steps undertaken and the scale of production should also be provided. Equipment should, at least, be identified by type (e.g., tumble blender, in-line homogeniser) and working capacity, where relevant. Steps in the process should have the appropriate process parameters identified, such as time, temperature, or pH. Associated numeric values can be presented as an expected range. Numeric ranges for critical steps should be justified in Section 3.2.P.3.4. In certain cases, environmental conditions (e.g., low humidity for an effervescent product) should be stated. 3.2.P.3.4 Controls of Critical Steps and Intermediates (name of the finished product, dosage form) Critical Steps: Tests and acceptance criteria should be provided (with justification, including experimental data) performed at the critical steps identified in 3.2.P.3.3 of the manufacturing process, to ensure that the process is controlled. Intermediates: Information on the quality and control of intermediates isolated during the process should be provided. 3.2.P.3.5 Process Validation and/or Evaluation (name of the finished product, dosage form). Process validation protocol (should outline the formal studies planned for the production scale batches) or / and Process Validation Report should be provided. (Which include Description, documentation, and results of the validation studies for critical steps or critical assays used in the manufacturing process). Validation of the sterilization process or aseptic processing or filling should be provided . 3.2.P.4 Control of Excipients (name of the finished product, dosage form) 3.2.P.4.1 Specifications (name of the finished product, dosage form) The specifications for excipients should be provided. (if compendial provide the monographs). 3.2.P.4.2 Analytical Procedures (name of the finished product, dosage form) The analytical procedures used for testing the excipients should be provided (if compendial provide the monographs). Also provide Certificate of Analysis of each excipient. 3.2.P.4.3 Validation of Analytical Procedures (name of the finished product, dosage form) For Pharmacopoeial Excipients (Not Applicable). For non-compendial excipients, Analytical validation information, including experimental data, for the analytical procedures used for testing the excipients should be provided, where appropriate. 3.2.P.4.4 Justification of Specifications (name of the finished product, dosage form) For Pharmacopoeial Excipients (Not Applicable). For non-compendial excipients , Justification for the proposed excipient specifications should be provided, where appropriate. 3.2.P.4.5 Excipients of Human or Animal Origin(name of the finished product, dosage form) For excipients of human or animal origin, EDQM certificate of TSE/BSE free certificates or certificate from health authorities should be provided. 3.2.P.4.6 Novel Excipients (name of the finished product, dosage form) If included in the drug formula (full details if used for the first time in a drug product.) 3.2.P.5 Control of Drug Product (name of the finished product, dosage form) 3.2.P.5.1 Specification(s) (name of the finished product, dosage form) The specification for the drug product should be provided. PARAMETERSPECIFICATIONS METHOD & REFERENCE 3.2.P.5.2 Analytical Procedures (name of the finished product, dosage form) The analytical procedures (Method of Analysis) used for testing the drug product should be provided. 3.2.P.5.3 Validation of Analytical Procedures (name of the finished product, dosage form) Note : if the analytical procedures used in the control of the drug product are Pharmacopoeial then verification is required which include: System suitability (tailing factor, resolution, stability of solution, theoretical plates,..). Selectivity including spiking (to prove resolution from excepients), stress conditions testing and purity of the peak (the method used to prove the purity of the peak should be stated). Linearity & Accuracy -Validation of method of analysis, including experimental data, for the analytical procedures used for testing the drug product, should be provided (Assay, impurities, dissolution..) 3.2.P.5.4 Batch Analyses (name of the finished product, dosage form) A description of batches and results of batch analyses should be provided, Description of batches as the following : DRUG NAME & CONC.  BATCH NO. MANUFACTURING DATE MANUFACTURING SITE PACKAGE TYPE BATCH SIZE &TYPE (Pilot, Production)  Results of batch analyses: Test Parameters Acceptance criteria BATCH NO. BATCH NO. BATCH NO.  Results ResultsResults A copy of the original analysis certificates for all these batches are included at the end of Part 3.2.P as regional information (3-2-R). 3.2.P.5.5 Characterization of Impurities (name of the finished product, dosage form) Information on the characterization of impurities should be provided, it could be referred to Module 3, Drug substance section "3.2.S.3.2 Impurities". 3.2.P.5.6 Justification of Specification(s) (name of the finished product, dosage form) Justification for the proposed drug product specification should be provided (if not compendial). 3.2.P.6 Reference Standards or Materials (name of the finished product, dosage form) Refer to Module 3, section "3.2.S.5 Reference Standards or Materials". 3.2.P.7 Container Closure System (name of the finished product, dosage form) A description of the container closure systems should be provided (and critical dimensions, with drawings where appropriate)., along with specification and Method of Analysis(Where appropriate). For non-functional secondary packaging components (e.g., those that neither provide additional protection nor serve to deliver the product), only a brief description should be provided. For functional secondary packaging components, additional information should be provided. 3.2.P.8 Stability (name of the finished product, dosage form) 3.2.P.8.1 Stability Summary and Conclusion (name of the finished product, dosage form) The types of studies conducted (Accelerated, Long term), protocols used, and the results of the studies should be summarized. The summary should include, conclusions with respect to storage conditions (labeling statement) and shelf-life that will be applied on the product indented to be marketed in our country. and, if applicable, in-use storage conditions and shelf life. Provide Special stability tests for different dosage forms(e.g. inverted stability study, .) if applicable. Summarize Forced degradation studies and stress condition (i.e. Photo stability studies) if applicable. 3.2.P.8.2 Post-approval Stability Protocol and Stability Commitment (name of the finished product, dosage form) The post-approval stability protocol and stability commitment should be provided: To Complete Real Stability Data (to cover shelf life) on pilot batches (if not completed at time of submission) and Real Stability Data on production batches (if not submitted with file) once they are available as annual report. Ongoing stability (Real data as annual report). 3.2.P.8.3 Stability Data (name of the finished product, dosage form) Results of the stability studies should be presented for 3 batches: Accelerated (40 2C / 75% RH 5%)minimum time period at submission (6 months) Long term (30 2C / 60% RH 5% Zone) minimum time period at submission (12 months) with a commitment to cover the shelf life once available. Provide Supportive stability data (if Available). For biosimilars: the quality sections (should include comparative studies with reference drug , beside his own ). Module 4: Nonclinical Study Reports 4.1 TABLE OF CONTENTS A Table of Contents should be provided that lists all of the Nonclinical Study Reports and gives the location of each study report in the Common Technical Document. 4.2 STUDY REPORTS The study reports should be presented in the following order 4.2.1Pharmacology 4.2.2Pharmacokinetics 4.2.3Toxicology 4.3 LITERATURE REFERENCES For Generic : Module 4 (Not applicable ).Literature References may be included. For the biosimilars: non-clinical studies are required. Module 5: Clinical Study Reports 5.1 TABLE OF CONTENTS A table of contents for the study reports should be provided. 5.2 Tabular Listing of All Clinical Studies 5.3 Clinical Study Reports Reports of Biopharmaceutic Studies Bioavailability (BA) Study Reports 5.3.1.2 Comparative BA and Bioequivalence (BE) Study Reports: For Generic: Provide Bioequivalence Study report (format & content submitted according to the data specified in BE registration criteria) which includes: -Table of content of BE -Summary report -In-vitro testing -In-vivo study design -Assay methodology Validation -Pharmacokinetic Parameters of BE -Statistical Analysis -Appendices (for Detailed Analysis) 5.3.1.3 In vitro-In vivo Correlation Study Reports 5.3.1.4 Reports of Bioanalytical and Analytical Methods for Human Studies For Generic: Summary Bioequivalence tables: - Reanalysis of Study Samples - Summary of Standard Curve and QC Data for Bioequivalence Sample Analyses - SOPs Dealing with Bioanalytical Repeats of Study Samples 5.3.2 Reports of Studies Pertinent to Pharmacokinetics using Human Biomaterials For Generic: Not Applicable Reports of Human Pharmacokinetic (PK) Studies For Generic: Should be provided, If BE study not submitted (Justified) Reports of Human Pharmacodynamic (PD) Studies For Generic: Should be provided, If BE study not submitted (Justified) Reports of Efficacy and Safety Studies For Generic: Not Applicable Reports of Post-Marketing Experience Risk management Plan(where appropriate) . PSUR to be submitted after product placed in the market. Case Report Forms and Individual Patient Listings For Generic: Not Applicable 5.4 Literature References For originator drugs: only the Literatures Pertinent to the Claimed Indication(s) are required. For Generic: Optional , the Literature References for the originator drug(Pertinent to the Claimed Indication(s)) should be included in case where originator drug is not registered in Jordan. For Generic module 5 should be submitted first & then after approval of the Bioequivalence studies , all the modules 1,2,3 should be submitted & a copy of JFDA committee approval of the B.E or the Comparative Dissolution Profile should be provided in the file. For biosimilars: the clinical studies(comparative ) are required. For a Comprehensive Table of Contents Headings and Hierarchy please go to: -Volume 2B Notice to Applicants Medicinal products for human use:  HYPERLINK "http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-2/b/update_200805/ctd_05-2008.pdf" http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-2/b/update_200805/ctd_05-2008.pdf Acronyms: EXF: Ex-factory price WSP: Whole Sale Price EDQM: European Directorate for Quality of Medicines Certification unit. TSE CEP: Transmi'(./3ACFRZ[dstɽɱ{l]N{?hV7hac5>*CJ.\aJ.hV7hV75>*CJ.\aJ.hV7h7l$5>*CJ.\aJ.hV7hS{5>*CJ.\aJ.hV7hF5>*CJ.\aJ.h2`hS5CJ.\aJ.h5CJ.\aJ.h2`h2`5CJ.\aJ.hlJ5>*CJ.\aJ.h5>*CJ.\aJ.hm.X5>*CJ.\aJ.#jh%h%5CJ.U\aJ.h2`5>*CJ.\aJ.hJKv5>*CJ.\aJ. CDEFt$V7$8$H$]^Va$gdS{$7$8$H$]^a$gdac$7$8$H$]^a$gd$7$8$H$]^a$gd%$7$8$H$]^a$gdV7%tvwx{|ƷՙvfYOYEYv9hdr5>*CJ0\aJ0hqCJ(_H,aJ(h8CJ(_H,aJ(hm.Xhm.XCJ(_H,aJ(hm.XhS{CJ(Z_H,aJ(o(hm.Xhm.XCJ(Z_H,aJ(o(hm.Xhm.XCJ(aJ(hm.XCJ(aJ(hV7hF5>*CJ.\aJ.hV7h p5>*CJ.\aJ.hV7hR5>*CJ.\aJ.hV7hac5>*CJ.\aJ.hV7h9J5>*CJ.\aJ.hV7hR5CJ.\aJ.hV7hF &5CJ.\aJ.8 9 uu "dh7$8$H$]^gddr "dh]^gddrV7$8$H$]^Vgd\;V7$8$H$]^Vgd{ O$V7$8$H$]^Va$gdS{$V7$8$H$]^Va$gd8$V7$8$H$]^Va$gdm.X  1 r s t u 6 7 źЁyqj_Th-h CJ aJ h-h-CJ aJ h-h-hYyGCJ aJ hacCJ aJ hSCJ aJ hhCJ aJ h CJ aJ hhLCJ aJ hX"hLCJ aJ hLCJ aJ h\;h2`CJ aJ h\;h\;CJ aJ h\;CJ aJ hZi 5>*CJ,\aJ,h\;h\;5>*CJ,\aJ,h2`5>*CJ0\aJ07 8 9 ? H g m n o   0 ? ļߴߴr_O_r *hV!D5CJ \^J_H,aJ % *hpQh5CJ \^J_H,aJ "hh5CJ \^J_H,aJ h5CJ \^J_H,aJ hhCJ aJ hhLCJ aJ h CJ ZaJ o(hLCJ aJ h CJ aJ hCJ aJ hX"hCJ aJ hCJ aJ hX"hLCJ aJ h7CJ ZaJ o(h-hLCJ aJ  @ |    8 vj dh^gddr $^a$gdI@$ "dh]^a$gddr "dh7$8$H$]^gd $ "dh7$8$H$]^a$gddr$ "dh7$8$H$]^a$gdq "dh7$8$H$]^gdV!D ? @ K P Q R V \ ] g j z | ȷ䨷wgWOD*B* CJ _H,aJ phphL>*B* CJ _H,aJ phphThTB* CJ aJ php hThT>*B* CJ aJ php hTh>*B* CJ aJ phphThLB* CJ aJ php hThL>*B* CJ aJ phph!>*B* CJ aJ phphPG>*B* CJ aJ phphq>*B* CJ aJ phphhLCJ ZaJ o(      6 7 8 9 B Ǹui]NhohF5>*CJ$\aJ$hZi B*CJ$aJ$phXEh(TB*CJ$aJ$phXEhdrh(TB*CJ$aJ$phXE&hdrh(T5>*B*CJ$\aJ$phXEheR>*CJaJh9#b5CJ\aJh\;B* CJ aJ phph!h\;B* CJ aJ phph!h!CJaJh!h CJ aJ h!h!CJ aJ h~CJ aJ h CJ aJ h!CJ aJ 8 9 g + ,RgSdh7$8$H$]^gd. & FVdh7$8$H$]^`Vgd. & FVsdh7$8$H$]^V`sgdEVdh7$8$H$^VgdSA & FVrdh7$8$H$^V`rgddr & FVsdh7$8$H$^V`sgd~ & Fadh7$8$H$`agd~ dh^gddr B C V f g h   + , = > E I Z c l t u ~sh`UJ?h(ThCJ aJ h(Th1^CJ aJ h(ThcCJ aJ h(TCJ aJ h(ThPCJ aJ h(Th pCJ aJ h(Th*/vCJ aJ h(Th,CJ aJ h(ThCJ aJ h(ThCJ aJ hSchpQCJ aJ h~h!CJ aJ h~CJ aJ h p5>*CJ$\aJ$hohE$5>*CJ$\aJ$hohF5>*CJ$\aJ$hohF5CJ$\aJ$ &,.0RZٳٟ~s~sg_T_gGgh8wh.0JCJ aJ h.h.CJ aJ h.CJ aJ jh.CJ UaJ h(Th\CJ aJ h(ThI@CJ aJ h(Th,OzCJ aJ h(ThCJ aJ 'h(Th0J<B*CJ ZaJ ph%h(ThcB*CJ aJ mH phsH %h(ThB*CJ aJ mH phsH )h(Th0JB*CJ aJ mH phsH !h(Th0JB*CJ aJ phLNPRb-.<=xyǼ{ndnWh3h~CJ_H,aJh~CJ _H,aJ h3h3CJ _H,aJ h3h3CJZaJh~CJaJh3CJZ_H,aJo(h.CJaJhprCJaJh3h3CJZ_H,aJo(h3h3CJaJh3h~CJaJh3h3CJ aJ h3CJ aJ h~CJ aJ h(ThSACJ aJ hcCJ aJ =LM*}}}} dhgdZi  gdZi dh7$8$H$gdhk dh7$8$H$gdi & F adh7$8$H$]`agdih7$8$H$]^hgd~ & FVdh7$8$H$]^`Vgd.dh7$8$H$]^gd. +KLMQUjkmƻ|tltdYNtC:hZi >*CJaJhA h/'CJaJhA hA CJaJhA hhkCJaJhhkCJaJhfuCJaJhiCJaJh.hsm>*CJaJh.hN>*CJaJhwdh~5CJ,\aJ,hi5CJ \aJ hwdhN5CJ \aJ hsm5CJ \aJ hwd5CJ \aJ h~5CJ$\aJ$h~h~CJ_H,aJh~CJ_H,aJh3h3CJ_H,aJ$'()*4RV_hiuv234°ࡓzoghlCJaJh[/hlCJaJh< |h< |5CJ$\aJ$h< |5CJ$\aJ$hZi hF5CJ$\aJ$hZi hF5>*CJ$\aJ$"jh< |CJUaJmHnHuh< |CJaJhZi h/'CJaJhZi hZi CJaJhZi CJaJhZi h.CJaJh.h.>*CJaJ%3445Yyye & Fdh7$8$H$]gdZi $dh7$8$H$]^a$gd< |"$ & F rdh7$8$H$]^r`a$gd< |Gdh7$8$H$]GgdZi Gdh7$8$H$]Ggd< |hd7$8$H$]^hgd< | & Fad7$8$H$]`agd< | $*+,-12345WXY]Ⱥxm^M hV!Dh{56CJ\]aJh< |hd5>*CJ\aJh< |5CJ\aJh65CJ\aJhV!Dh6CJaJhdCJaJhV!DhdCJaJhd5CJ\aJhV!Dh5CJ\aJhV!Dh65CJ\aJh< |hg5>*CJ\aJhd5CJ \aJ hl5CJ \aJ hlCJaJh.$hlCJaJ]a0<@BXYнmWD6hV!Dh{6CJ]aJ%hV!Dh{B* CJ^J_H,aJph+hV!Dh{6B* CJ]^J_H,aJph+hV!Dh{6B*CJ]^J_H,aJphhV!Dh{CJ^J_H,aJhdCJ_H,aJhCJaJhV!Dh{CJaJhV!Dh{5CJ\aJ$hV!Dh{56CJ\]_H,aJ hV!Dh56CJ\]aJ hV!Dh{56CJ\]aJhd56CJ\]aJYYtT & F dh7$8$H$]^`gd/ dh7$8$H$]gd/ & F dh7$8$H$]gd/ & F dh]gdd dh7$8$H$]^gd & F dh7$8$H$]^`gdd dh]^gdZi 19:#$%=ZcdeŽŬ}m]J$hV!Dh |h56CJ\]_H,aJh/56CJ\]_H,aJhV!D56CJ\]_H,aJ hV!Dh |h56CJ\]aJhV!Dh |h6CJ]aJhV!Dh |h6CJ]_H,aJ! *h)>h |h6CJ]_H,aJh/CJaJh{CJaJhV!Dh{CJaJhV!Dh |hCJ_H,aJhV!Dh |hCJZ_H,aJo(hV!Dh |hCJaJekϹn]RG8)h/h)>B*CJaJphh/h |hB*CJaJphhV!Dh |hCJaJh)>h)>CJaJ hV!Dh |h56CJ\]aJ$hV!Dh |h56CJ\]_H,aJhV!DhV!DCJ_H,aJhV!Dhb,CJ_H,aJhV!Dhb,CJaJ%hV!Dhb,B* CJ^J_H,aJph+hV!Dhb,6B* CJ]^J_H,aJph+hV!Dhb,6B*CJ]^J_H,aJphhV!Dhb,CJ^J_H,aJh/CJ^J_H,aJ3"#AZvzjGdh]G^gdopdh7$8$H$]gdop 7$8$H$gdGdh7$8$H$]Ggd)> & Fdh7$8$H$gd< |hdh7$8$H$^hgd< |hdh7$8$H$]^hgd)>hdh7$8$H$]^hgdSc & Fdh7$8$H$]gd/ 134gh !"#?@Aü}rng\M>h< |hg5>*CJ \aJ h< |h< |5>*CJ \aJ h5CJ \aJ hhhh)>hCJaJh< |h< |5>*CJ\aJh< |hg5>*CJ\aJh< |h< |5CJ\aJ h)>_H,h)>h |h_H,h< | h)>h |hh)>h)>CJaJhV!Dh |hCJaJh/h |hCJaJh/hpQCJaJh/hpQB*CJaJphAYZuv³um^P^Bh{hN5CJ$\aJ$h{hF5CJ$\aJ$h{hF5>*CJ$\aJ$hPGCJaJhophT!CJaJhJ"CJOJQJ^JaJhB6hy.>*CJaJh)>h5CJ$\aJ$h)>hCJaJhB6hg5>*CJ\aJ hophCJOJQJ^JaJhopCJOJQJ^JaJhopCJOJQJ^JaJ hophopCJOJQJ^JaJv  !"q j$ & Fdh<7$8$H$^`a$gdB6$ & Fd<7$8$H$^`a$gdEk 7$8$H$gd/ s A$^a$gdC_ r7$8$H$^rgdEk A$^a$gdeQ & Fr]^r`gdEk]gdIGdh7$8$H$]GgdJ"     !"9GXYoƷvk\P\A2hth?&B*CJaJphhth,4B*CJaJphh/FB*CJaJphhth2B*CJaJphh=qh"CJaJheQhC_>*CJ aJ h1i5>*CJ \aJ heQhC_5>*CJ \aJ h{hC_5CJ$\aJ$h{hC_>*CJ$aJ$h{hC_5>*CJ$\aJ$hEk5>*CJ$\aJ$h{hEk5>*CJ$\aJ$h{heQ5CJ$\aJ$ h{hF5CJ$Z\aJ$o(opqrw      & 5 d e ɺvnvcnvTLvAvAhth?&CJaJhpQCJaJhth%0B*CJaJphhthJCJaJh(CJaJhth2CJaJhB6CJZ_H,aJo(hB6CJaJhEkCJaJhtCJaJh/FCJaJhU B*CJaJphhth2B*CJaJphhth 5 B*CJaJphhB6B*CJaJphh,4B*CJaJphhth=qB*CJaJphe w !!!!! !/!0!g!!!!":"J"K"L"M"S"T"t"""""ynhth\@CJaJhth,4CJaJhth,4B*CJaJphhthi^]CJaJhthRCJaJhB6CJaJhthJ"CJaJhCJaJhtho{CJaJhthJCJaJhJCJaJhU CJaJhth?&CJaJhth2CJaJ+ K"L"'#k#}#$J%%9&Q&R&&&c7d]c^7`gdB6 ;dh7$8$H$]^;gdH7 7$8$H$gdB6 dh7$8$H$gdB6 & Fdh7$8$H$^gdB6dh7$8$H$]^gdJ"&dh7$8$H$]`&gdB6 """"""##$#&#'#O#j#k##########################ƾ糨}}}}}rjbjheQCJaJh`CJaJhthvCJaJhU CJaJhEkCJaJhthgCJaJhJ"CJaJhxCJaJhth(CJaJhth,4CJaJh(CJaJhth\@CJaJhthLXCJaJhthoCJaJhthi^]CJaJhthi^]5CJ\aJ&##$$\$$$$$$$$$$$I%J%%%%%9&>&N&Q&ǶzhVhBhhh&hB6hA6>*B*CJ]aJph#hB6hv{6B*CJ]aJph#hB6hA6B*CJ]aJph#hB6hx6B*CJ]aJph)hB6hx56B*CJ\]aJph)hB6hA56B*CJ\]aJph hAhA56CJ\]aJhgCJaJheQCJaJhthoeCJaJhth`CJaJh`CJaJh`h`CJaJQ&R&[&a&v&&&&&&&&&&&''!'#'&'''0'1'2'9'D'E'źskc[PE[hhhz/CJaJhhhhCJaJhhCJaJh MCJaJhB6CJaJhhhMTCJZ_H,aJo(hhhMTCJaJhhhltCJaJhhhTCJaJhhh|]CJaJhhhDCJaJhhht!CJaJhhhiZoCJaJhh%35CJ\aJh=[5CJ\aJhhBK5CJ\aJhv{5\_H,&2'''(((()_))))*y  U"c7d7$8$H$]c^7gdJ" 3 U"7dh]^7gdH7 !G7d]G^7gdJ"7dh7$8$H$^7gdH7;dh7$8$H$^;gdH7 77$8$H$^7gdH7c7d7$8$H$]c^7gdB6 E'F''''''''''''''''(((((((({s{od`RDhLXh+?5CJ\aJhLXhBK5CJ\aJhOhxh$"CJaJhkhxCJaJh|vhkCJaJh|vhk5CJ\aJ hhhBKhhhUICJaJhhhkCJZ_H,aJo(hhh~`wCJaJhhh%fCJaJhhh|]CJaJhhCJaJh|TJCJaJhhhhCJaJhhhTCJZaJo(((((((())))T)^)_)v){))))))))ֽ֖xmbxmxZOAhVh45CJ\aJh'h/0CJaJhy;CJaJh'h%3CJaJh'hy;CJaJh|TJCJaJh'hHCJaJh'h;ACJaJh'h+?CJaJh'h%35CJ\aJh'hBK5CJ\aJh5CJ\aJh'hH5CJ\aJh'h+?5CJ\aJhLXh+?5CJ\aJhLXhLX5CJ\aJ)))))))*****;+<+++++++++ɻ}u}u}umaRCh/0hc5>*CJ\aJh/0h/05>*CJ\aJh/05>*CJ\aJh1iCJaJhCJaJhVhcCJaJhVhc5CJ\aJ *h/0hc5CJ\aJhVh CJaJhVhsCJaJhVh45CJ\aJhVh5CJ\^JaJh5CJ\aJhVhXR5CJ\aJhVh5CJ\aJ**+,,,,,,/1113~7d7$8$H$]~^7gdJ" "G7d7$8$H$]G^7gd/0  "G7d7$8$H$]G^7gd/0  U"c7d7$8$H$]c^7gdJ"  U"c7dh7$8$H$]c^7gdJ" +,,,O,P,,,,,,,---(-Z-[-f-g---..b.c...////F/g/˺È}uÈÈÈÈÈÈmbZhCJaJh+3Mh+3MCJaJhSfwCJaJhJ"CJaJhVhsLCJaJhVhSfwCJaJh/0h5>*CJ\aJh/0hc5>*CJ\aJh;>*CJaJh/0>*CJaJhCJaJhVhcCJaJh/0h1i5CJ\aJh/0h5CJ\aJh/0hXQ-5CJ\aJ!g/h/i///00Q0R00000G1H111111&2'2y2z22233j3k3337484444444"5#5t5u55566_6`6666677a7c77788H8I8x88899i9j9999hWCJaJh/0h+3M5>*CJ\aJh;5>*CJ\aJh+3MCJaJh+3Mh+3MCJaJhCJaJhRCJaJI3466c7H8I8x899:,;9;s 77d7$8$H$^7gdJ" 7G7d7$8$H$]G^7gdJ" 77d^7gdJ"G7d7$8$H$]G^7gd/0G7d7$8$H$]G^7gdJ"Gd7$8$H$]G^gdR7d7$8$H$]^7gd/0 99999:::,;8;v;w;;;;;;;;;;<<z={=|=}=ܾyqf[PEh;5CJ\aJhW5CJ\aJh+3Mh-#CJaJh+3Mh;CJaJhsLCJaJh+3MhsLCJaJh,CJaJh+3Mh^CJaJh+3Mh^5CJ\aJh+3Mhi,~CJaJh+3Mh+?5CJ\aJh+3Mh45CJ\^JaJh+3MhXR5CJ\aJh+3Mh5CJ\aJh+3Mh45CJ\aJh/0CJaJ9;w;;;;<={=|=}==>>?sd7$8$H$]^gdd7$8$H$^gd d^gd7d7$8$H$^7gd/0 77dh7$8$H$^7gdJ" 77dh^7gdJ" 77d7$8$H$^7gdJ" & F 7d7$8$H$gdJ" }========>>b>c>>>??X?Y?@@N@O@@@@@AAAAA AAABAʻٞ{{peWh h;5CJ\aJh^5CJ\aJh,h^CJaJh,CJaJh CJaJhLhCJaJh h^CJaJh h^5CJ\aJh/0hsLB*CJaJphh/0h$B*CJaJphh/0h-#B*CJaJphh h-#CJaJh hXR5CJ\aJh h45CJ\aJ!?AAACAGBTBCDDDgDD/EEEF,d7$8$H$],^gdWd7$8$H$^gdWdh7$8$H$^gdWd7$8$H$]^gd<d]^gdd7$8$H$]^gdBACAGBTBqBBBBCCCCCDDDD(D8D:DWDgDDDDøððsesWIWhhV5CJ\aJhh<5CJ\aJhh%35CJ\aJhhBK5CJ\aJhh6<5CJ\aJh*hBK5CJ\aJhh;CJaJhWCJaJhCJaJhh_ HCJaJhhCJaJhhCJaJhh5CJ\aJh h-#CJaJh h-#5CJ\aJDDD.E/E=E>EEEEEEFFOFPFFFFFFFFFFFFFFFFFϹϹϹti^Vhy;CJaJh<h%3CJaJh<h"CJaJh<hCJaJh<hVCJaJh<h 5CJ\aJh<h5CJ\aJh<hWCJaJhUECJaJh<CJaJhh^5CJ\aJhh^CJaJhh*CJaJhWCJaJhCJaJhh<CJaJFFFFFWGbGGGHHZHHH 7,d7$8$H$],gd` ,d7$8$H$],^`gd` ,d7$8$H$],gd` ,dh7$8$H$],^gdW,d],^gd` ,],^gdW,7$8$H$],^gdW FFGGG G"G%G,G.G1G5GHGTGUGVGWGXGaGkGlGGGGHHHH˻򘊣ˊtdTdIhURhHkCJaJhURh 6CJ]_H,aJhURhn}6CJ]_H,aJhURhn}CJaJhURhUECJaJhURhUE5CJ\aJhURh_ HCJaJh;5CJ\aJhUR5CJ\_H,aJhUR5CJZ\_H,aJo(hUR5CJ\aJhURh%35CJ\aJhURh*5CJ\aJhURhBK5CJ\aJHHH#H$HZHHHHHAIBIIIIIIIIIIIIIIɼrg[grg[gSEhURh:+5CJ\aJh)YCJaJhURh)Y>*CJaJhURh)YCJaJhURh)Y5CJ\aJhURh-+ CJaJh:CJaJhURhtTCJaJhURhtT5CJ\aJhURh/06CJ]_H,aJhdR06CJ]_H,aJhURhdR0CJaJhUR5CJ\aJhURhdR05CJ\aJhURh/0CJaJhHkCJaJHHIIIIJgJhJiJJo,d7$8$H$],gdUR,;d7$8$H$],^`;gdW ,d7$8$H$],gdW,pd7$8$H$],^p`gdUR,d7$8$H$],^gd/0,d7$8$H$],^gd:,d7$8$H$],^gd` IIJfJgJhJiJJJJJ:K;K>KFKGKhKKKKKKKKKܶܦzl^SHS@h:CJaJhURhuCJaJhURh:CJaJhURh:5CJ\aJhURh%35CJ\aJhURh@&5CJ\aJhURhBK5CJ\aJh/0CJaJhWCJaJhURh:+6CJ]_H,aJhURh-+ CJaJhURh/0CJaJh;CJaJh:+CJaJhURh:+CJaJhURh:+5CJ\aJhW5CJ\aJJJ;KKKKKKgLL{g,dh],^`gdW,dh7$8$H$],^gd/0,dh7$8$H$],^gdW,;dh7$8$H$],^`;gdW,dh7$8$H$],^`gdW,d7$8$H$],^`gdUR,d7$8$H$],^gdW KKKL.L0L1L2L4L6L7L8L;LMMMrNsNtNuNvNwNxN||||| d7$8$H$^gdUR nd7$8$H$gdUR$d7$8$H$]^a$gdWd7$8$H$]^gdW d7$8$H$gdW,dh7$8$H$],^gdW,dh],^`gdW L%M2MMMMNNNN=NFN^NpNqNrNsNxN}NNNNNNNǼǮǮǣzl^lPlEh78h]CJ aJ h78h/5CJ \aJ h78h_ H5CJ \aJ h78h]5CJ \aJ h_ HCJaJhURh_ HCJaJhURhfCJaJhURhy;CJaJhURh CJaJhURh$5CJ\aJhURhX@CJaJhURh$CJaJhURh CJaJhURhWCJaJhWCJZ_H,aJo(hURhstiCJaJxNyNzN{N|N}NNN/OOPm SWd7$8$H$]^S`Wgdt SWd7$8$H$]^S`Wgd78 SZd7$8$H$^S`Zgd78 `d7$8$H$^``gd78 d7$8$H$^gd78 d7$8$H$^gd_ H NNNNNNO O.O/O5OtOuO}OOOOOOO@PKPOPPPYPgPhPPP˽˲tit^SKhTCJaJhWh&~CJaJhWhsLCJaJhWh1CJaJhWhBCJaJhWhTCJaJhWhtCJaJh78CJZ_H,aJo(h78CJaJhWCJaJhWh]CJaJhWh/5CJ\aJhWh]5CJ\aJhW5CJ\aJhWh*5CJ\aJhWh E5CJ\aJPPPPPPPPP~$$&`#$/1$If]^a$gd;$$&`#$/1$Ifa$gd;$$&`#$/1$If]a$gd;$$&`#$/1$If]^a$gd;$($&`#$/1$If^(a$gd;PPPPPPPPP QQQQQQQQQ%Q&Q'QBQ^Q_Q`QgQiQxQ}Q~QQ컰{k`UhWh+GCJaJhWh]CJaJh785CJZ\_H,aJo(hWh/5CJ\aJh785CJ\aJhWh]5CJ\aJhWh*5CJ\aJhWh;CJaJh;CJaJh;5mH sH h;CJH*mH sH h;CJmH sH h;5CJmH sH h;mH sH h;5CJmH sH PPPPPPuYAAA$d$&`#$/1$Ifa$gd;$(d$&`#$/1$If^(a$gd;kd$$If4r g6# p'TT 6`>#af4PPP$(d$&`#$/1$If]^(a$gd;$d$&`#$/1$Ifa$gd;PPkd$$If4ֈ /g6# 88'TT 6`<>#af4p<PPPPPPr$)(d$&`#$/1$If])^(a$gd;$d$&`#$/1$If]^a$gd;$d$&`#$/1$Ifa$gd;$ d$&`#$/1$Ifa$gd;(d$&`#$/1$If^(gd;PPQ Q Qw[??$ d$&`#$/1$Ifa$gd;$(d$&`#$/1$If^(a$gd;kd$$If4r g6# p'TT 6`>#af4 Q Q Q Q$(d$&`#$/1$If]^(a$gd;$d$&`#$/1$Ifa$gd; QQkd$$If4ֈ /g6# 88'TT 6`<>#af4p<QQQQQQ$(d$&`#$/1$If]^(a$gd;$d$&`#$/1$Ifa$gd;$ d$&`#$/1$Ifa$gd;$(d$&`#$/1$If^(a$gd;QQQQQw[?'$d$&`#$/1$Ifa$gd;$ d$&`#$/1$Ifa$gd;$(d$&`#$/1$If^(a$gd;kd$$If4r g6# p'TT 6`>#af4QQQQ?kd$$If4r g6# p'TT 6`>#af4$(d$&`#$/1$If]^(a$gd;$d$&`#$/1$Ifa$gd;QQQ~Q[R\RRCSeT}iJ$ 7Srd7$8$H$]^S`ra$gd78Wd7$8$H$]`Wgd78d7$8$H$]^`gd78Wd7$8$H$]^`Wgd78 Sd7$8$H$]^Sgd78 7rrd7$8$H$]^r`rgd78 SWd7$8$H$]^S`WgdtQDRFRXRYRZR[R\ReRgRRRRRRRRRRRRRRRS SSS}m`}RG}mhWh]CJaJhWh5CJ\aJh785CJ\_H,aJh785CJZ\_H,aJo(hWh/5CJ\aJh785CJ\aJhWh]5CJ\aJhWhs5CJ\aJhWhT5CJ\aJhWh s`5CJ\aJhWh/5CJ\aJhWh+GCJaJhWh+G5CJ\aJhWhTCJaJSS6SBSCSESSeTgTsTTTTTTTTTTTTOUXUYUZU[UfUpUsUUUUʿՓՅʩzood\QՓՅhWh;CJaJh6<CJaJhWhFCJaJhWhh3CJaJhWh^KCJaJhWh/5CJ\aJhWh s`5CJ\aJhkCJaJhWh6<CJaJhWh9-CJaJhWhBCJaJhWh]CJaJhWh]5CJ\aJh785CJZ\_H,aJo(h785CJ\_H,aJeTfTgTTZU[UU'VVVV0W{cGd7$8$H$]G^`gdkGd7$8$H$]Ggdk  Gd7$8$H$]G^gd;Gd7$8$H$]G^gdkGd7$8$H$]G^gdd7$8$H$]gd+Sd7$8$H$]^Sgd+d7$8$H$]gd+ UUUUUUUUUUUVVV&V'V(V/V0V1VgVhVVVVVVVVVVVVVʿʦʛzodVVVʦhWh s`5CJ\aJhWh;CJaJhWhM~CJaJhWh _CJaJhWh9-CJaJhWhOCJaJhWh]CJaJhWh/5CJ\aJh]5CJ\aJh5CJ\aJhWh]5CJ\aJh+5CJ\_H,aJh+5CJZ\_H,aJo(h+5CJ\aJ!V0W1W=W>WiWuWwWWWWWAXBXXXXXXX YYYY Y>YMYPYYYYø߭߄ynycnXMhWh.LCCJaJhWhAr CJaJhWhTCJaJhWhCJaJhWhCJaJhWh`TCJaJhWhECJaJhWhM~CJaJh+CJaJhWhw!CJaJh5CJ\aJhWh/5CJ\aJhWh s`5CJ\aJhWh]5CJ\aJhFCJaJhWh]CJaJ0W1WWXXYLYYY]ZW\X\Y\{Gvd7$8$H$]G^`vgdkGd7$8$H$]G^gdkGd7$8$H$]GgdkGd7$8$H$]G^`gdkGd7$8$H$]G^`gdkGd7$8$H$]G^`gdk YYYYYYY Z Z ZZZ2ZNZ\Z]Z[[V\W\X\Y\c\d\\\\\\\\J]K]a]ɻ{sh{]U]U]h+CJaJhWhRCJaJhWh)CJaJhECJaJhWhqKCJaJhWh/5CJ\aJhWh]5CJ\aJh+5CJ\aJhWh s`5CJ\aJhWh;5CJ\aJhWh]CJaJhWhCJaJhWhM~CJaJhWh.LCCJaJhWhAr CJaJ!Y\\]_^|^^ _.____*```9aaad7$8$H$]^gd)d7$8$H$]^gd)dA$]^a$gd)$hd]gd)d7$8$H$]gd)d7$8$H$]^gd)a]b]]]]]1^2^^^_^{^|^^^^^^^^^^^^_ _ _ɻti\OAhWhEaCJZaJo(hWhEaCJ_HaJhWhku&CJ_HaJhWhCJaJh)5CJ\_H,aJh)5CJZ\_H,aJo(hWh/5CJ\aJhWh]5CJ\aJhWh s`5CJ\aJhWhE5CJ\aJhWhR5CJ\aJhWh/lwCJaJhWhECJaJhWhRCJaJh+CJaJ _ ___&_-_._/_0_6_?_@____________`)`S`U`````a*a8aaٴٴttlath;5CJ\aJhsLCJaJhWh/5CJ\aJh)5CJ\aJhWh/lw5CJ\aJhWh/lwCJaJhWhBKCJZaJo(hWhCJ_HaJhWhEaCJZaJo(hsLCJ_HaJhWhku&CJ_HaJhWhCJ_HaJhWhEaCJ_HaJ"aaaaaaaa3b4bAbCbObbb@crcceee$f@fNfOfBgCgggggh hh'h5h6hShܓ}uܓѓjhWhLm;CJaJh;CJaJhWhLCJaJhWh` nCJaJhWh/5CJ\aJh;5CJ\aJhWhCJaJhWhz>*CJaJhWh1j5CJ\aJh)5CJ\aJhWhz5CJ\aJhWh/lwCJaJhWhzCJaJ%aAbb>ccsdeeOfCggg7hrisii 7$8$H$gd/lw 7$8$H$^gd)7`7$8$H$^7``gd)`d7$8$H$^``gd)d7$8$H$^gd)d7$8$H$]^gd)%d7$8$H$]^`%gd)Shhhhhsiiiiiiiiij"j#j)j-j6j:jJjfjtjjjjjjjjkkk$k(k+k,kĹߠ|l_lh)5CJ\_H,aJh)5CJZ\_H,aJo(hWh3CJaJh;5CJ\aJhWh/5CJ\aJh)5CJ\aJhWhz5CJ\aJhWh;CJaJh;CJaJhOCJaJhWhUmCJaJhWhzCJaJhWhy%CJaJhWhQCJaJ%iiii#jujjjBkkkSllGmm{`d7$8$H$^``gd)7d7$8$H$^7gd) d7$8$H$gd)d7$8$H$^`gd)d7$8$H$^`gd) d7$8$H$gd;d7$8$H$^gd)d7$8$H$^gd),k-k5kAkvkkkkkk(lDlRlSlWlellllllGmOmYm`mmmmmmmmmmmnnǼttgt\hWh3CJaJh)5CJ\_H,aJhWh8CJaJhWhSL^CJaJhWh/5CJ\aJhWh?5CJ\aJh)5CJ\aJhWhPACJaJhWh?CJaJhWhzCJaJhWhz5CJ\aJh)5CJZ\_H,aJo(h;5CJZ\_H,aJo($mmpnnoo/p0p}ppqq-qBq$$1$If^a$gdt5 $$1$Ifa$gdz 7$8$H$^gdt5 7$8$H$`gd) 7$8$H$^gdO 7$8$H$gd+uX d7$8$H$gd)7d7$8$H$^7gd) npnxnnnnnnnnnnnnno*oDoHoToUoXokooooooooooo,p-p.p/pܣwwlaahWhHHCJaJhWh3CJaJhWh`FCJaJhWhPACJaJhWh^CJaJhWhPCJaJhWhP5CJ\aJh)5CJZ\_H,aJo(h)5CJ\_H,aJhWh/5CJ\aJhWh?5CJ\aJh)5CJ\aJhWh?CJaJ$/p0pRpnp|p}pppppppppppqqqq,q/q5qAqBqCqEqFqGqLqMqOqöΖzthd^T^h]CJmH sH  h]CJht5ht5OJQJmH sH  ht5CJ ht55CJ h^rH5ht5h^rH5ht5ht55h+uXCJaJht5CJaJh)5CJZ\_H,aJo(h)5CJ\_H,aJh)5CJ\aJhWh+uXCJaJhWh/5CJ\aJhWh+uX5CJ\aJhWhECJaJBqCqDqEqFqwlVH $$1$Ifa$gdz$$1$If]^a$gdz $1$Ifgdzkd$$IfP4F !5 & 0    4 Paf4FqGqHqIqJqwlVH $$1$Ifa$gdz$)$1$If])^a$gdz $1$IfgdzkdG$$IfP4F !5 & 0    4 Paf4JqKqLqMqNqwlVH $$1$Ifa$gdz$)$1$If])^a$gdz $1$Ifgdzkd$$IfP4F !5 & 0    4 Paf4NqOqPqQqRqqrrrrwjjjj]]]P 7$8$H$`gd< 7$8$H$^gd) 7$8$H$`gd)kd$$IfP4F !5 & 0    4 Paf4 OqPqRqtqqqqqqqqrrrrKr`rbrdrmrtr}rrɹ⡙ueXuJhWhvD5CJ\aJh<5CJ\_H,aJh<5CJZ\_H,aJo(h<5CJ\aJhWh5CJ\aJhWh;CJaJh+uXCJaJhWh+uXCJaJh)5CJ\_H,aJh)5CJZ\_H,aJo(h)5CJ\aJhWh/5CJ\aJhWh+uX5CJ\aJh;CJaJh\4]CJaJrrrrrsssssssst@tCtPtYtbtftntotptɾzi[iJ9!h;5B*CJ\_H,aJph33!h5B*CJ\_H,aJph33h;B*CJ_H,aJph33!h;hB*CJ_H,aJph33!hB*CJZ_H,aJo(ph33hB*CJ_H,aJph33'hhB*CJZ_H,aJo(ph33!hhB*CJ_H,aJph33hhB*ph33hhB*CJaJph33%hhB*CJaJmH ph33sH (hh>*B*CJaJmH ph33sH rsrsYtotptqtrt)u~~fY 7$8$H$^gd;^&#$+Dr/7$8$H$^gd;^&#$+Dr/7$8$H$gd; & F^&#$+Dr/7$8$H$gd;$ !^&#$+Dr/A$^a$gd; & F ^&#$+Dr/^`gd;$^&#$+Dr/^a$gd;ptqtrtsttt uuuu(u)u+u5u7uGucuruuuuuuuuĹzogZPoH@hCCJaJh;CJaJhCJ_H,aJhCJZ_H,aJo(hCJaJhWhHHCJaJhWh/5CJ\aJhWh5CJ\aJh;5CJ\aJhCJaJhsLCJaJh ,CJaJhWhCJaJhWhPACJaJhWhRCJaJ!h5B*CJ\_H,aJph33'h;h;5B*CJ\_H,aJph33)u*u+uruuuu vvvv,v@vAvPvav$($1$If](a$gdd$$1$If]^a$gdz($1$If](gd}s$($1$If](a$gdzd7$8$H$^`gd;d7$8$H$^gd;uuvv v@vNvPv\vvvwvvvvvvvvvvvvvwwwwwwwùyuyufWKWh>^CJaJmH sH hhCCJaJmH sH hNhCJaJmH sH hNhQhNCJmH sH hNCJmH sH hN5CJmH sH hi<5CJmH sH hCJaJhWh>^CJaJhLCJmH sH hL5CJmH sH hLhL5CJaJmH sH h}s5CJaJmH sH hL5CJaJmH sH h>^CJaJavvvwvxvyvzvO===(d$1$If](gdzkd{$$IfP4ֈ84<l(#x0$4 Paf4$$1$If]^a$gdnQszv{v|v}v~vv7kdn$$IfP4ֈ84<l(#x0$4 Paf4$y`d$1$If]y^`a$gdz$(d$1$If](a$gdzvvvvvvvvvvvv$$1$If]^a$gdF$($1$If](a$gdN$($1$If](a$gdF7$8$H$^`gd; vvvvvvwyydXX $$Ifa$gdN$(d$1$If](a$gdF(d$1$If](gdFskdM$$IfP4\3t"j  !4 Paf4wwwwwwwxxznnnneX 7$8$H$^gd. 7$8$H$gd dh^gd;7$8$H$^`gdCskd$$IfP4\3t"j  !4 Paf4wwwwwwwwwwwwx xx+x;x^xjxrxxxxxxxxyyy yy,y3yByΔ|q|fqf|X·hWhO5CJ\aJhWhSL^CJaJhWhPACJaJhWhCJaJh.5CJ\_H,aJh.5CJZ\_H,aJo(hWh/5CJ\aJhWhP5CJ\aJhWh5CJ\aJh.5CJ\aJhh;CJaJmH sH h;CJaJmH sH hCCJaJmH sH "xxByyyzWzXzYzzzn{o{{{,||$ ;W7$8$H$^;`Wa$gd. 7$8$H$gd ;7$8$H$^;gd.7$8$H$^`gd 7$8$H$^gd. 7$8$H$gd. 7$8$H$^gdBy{y|yyyyyyyyyyyyyy zzz*zWzXzYz[zbzezzzzzzzzɻɫɫ|qiɻɻ^ShWhCJaJhWhy;CJaJhSL^CJaJhWhvDCJaJhWhvD5CJ\aJ$hWhO5CJZ\_H,aJo(hWh/5CJ\aJh.5CJZ\_H,aJo(hWh5CJ\aJh.5CJ\aJhWhOCJaJhWhPACJaJhWhSL^CJaJhWhCJaJ zz({*{+{/{Y{m{n{o{{{{{+|,||||||||||| } }}}}}yn^Q^Qh25CJ\_H,aJh25CJZ\_H,aJo(h25CJ\aJhWhPACJaJhWh/5CJ\aJhWhO5CJ\aJhWhPA5CJ\aJhWh}sCJaJhCJaJhWh4}CJaJhWhSL^CJaJhWh|e$CJaJhWhCJaJhWhCJaJh.CJaJ|||;}}~~#$6m & F1$7$8$H$gd  & F1$7$8$H$gdh > 7$8$H$^gd.7$8$H$^`gd2^gd /u 7$8$H$^gd2 ;7$8$H$^;gd. S7$8$H$^Sgd2}}!}"})}2}:};}} ~*~t~u~v~w~~~|}ʼynf[PBhWhPA5CJ\aJhWhPACJaJhWh.CJaJhAMCJaJhWhy;CJaJhCJaJh /uh /u5\mH sH h /uh /u5\h /uhAM5\hWhAMCJaJh2hvD5CJ\aJhWhvD5CJ\aJh25CJ\aJhWh/5CJ\aJh25CJ\_H,aJh25CJZ\_H,aJo( ,6Z[klmʼrcWrcKKh CJ^J_H,aJhh >CJ^J_H,aJh hh >CJ^J_H,aJhh >hh >CJ^J_H,aJh h CJ^J_H,aJh.CJaJhWhPACJaJhWhvD5CJ\aJhWhvDCJaJhWh/5CJ\aJhWhPA5CJ\aJh25CJ\aJh25CJ\_H,aJh25CJZ\_H,aJo()z <=>? 7$8$H$]gdsL7$8$H$^`gd 7$8$H$^gd`$ 7$8$H$^gd2 1$7$8$H$gd.ց')9:;<=HIJMNUVZ[deyz׾sskkkk[hWhyCJOJ^JaJo(h`$CJaJhWh1CJOJ^JaJhWh1CJOJ^JaJo(hWh1CJaJhWhyCJaJhWhjCJaJhWhAMCJaJhWhPACJaJhWh/5CJ\aJhWhPA5CJ\aJh h.CJ^J_H,aJh.CJ^J_H,aJς ;<?NPT\止yeQ'h.hY=6B*CJ]_H,aJph'h.h^6B*CJ]_H,aJphhWh^6CJ]_H,aJ! *hWh^6CJ]_H,aJh.CJaJhWhPACJaJhWhAMCJaJhWh +CJaJh`$CJaJhWh@CJaJhWhyCJOJ^JaJo(hWhyCJaJhWhyCJOJ^JaJ\fmuƒÃă̓ïÛïxl]UD6huF[hC$f5CJ(\aJ(!huF[hC$f5>*CJ(\_H,aJ(hQVCJaJhsLh.B*CJaJphh.B*CJaJphh.h,B*CJaJph'h.h>!6B*CJ]_H,aJph'h.h6B*CJ]_H,aJph'h.h^6B*CJ]_H,aJph'h.hsL6B*CJ]_H,aJph'h.hY=6B*CJ]_H,aJph'h.hh >6B*CJ]_H,aJphƒÃă+EF  gd|% 7$8$H$gdC$f dh7$8$H$gd`$ & Fdh7$8$H$gd`$ 7$8$H$gd, 7$8$H$]gdsL^_*+EFQn…ƅ΅υхƸugVF9F9FhrX6CJ]_H,aJhN\hN6CJ]_H,aJ! *hN\hN6CJ]_H,aJh+uX5>*CJ \_H,aJ huF[h|%CJ _H,aJ huF[hC$fCJ _H,aJ  *huF[hC$f>*CJ _H,aJ hV5CJ8\aJ8h`$h5CJ\aJh`$hC$f5CJ\aJh`$hVCJaJh`$hV5CJ\aJh`$CJaJh`$hbCJaJh`$hb5CJ\aJх҅ӅԅՅօׅ؅مڅۅ܅݅ޅ߅ 7$8$H$gd"  gdrX 7$8$H$^gd+uXх҅ԅՅօׅ #aƆφІ5@Be˸zozozozazozozUJohrNh:CJaJ *hrNh:CJaJhrNhF5CJ\aJhrNhC$fCJaJhrNhC$f5CJ\aJh%wCJ0aJ0h%whC$fCJ0aJ0h%whC$f5CJ(\aJ(h%whC$f5>*CJ(\aJ(h%Hh\4]CJaJh`$CJaJh\4]CJaJh=CJaJh%wCJaJh%w5>*CJ \_H,aJ h,5>*CJ \_H,aJ  #aφІ5 7$8$H$gddr & F S7$8$H$gde<[ & F 7$8$H$gdF 7$8$H$`gdC$fdh7$8$H$`gde<[ dh7$8$H$gde<[ 7$8$H$gdC$f & FgdP 7$8$H$^gd+uXef҇Ӈ "#@APbcxyш³³ߨlZlZ"hrNhC$f5CJ\aJmHsH(hrNhC$f56CJ\]aJmHsH(hrNh#56CJ\]aJmHsH"hrNh#5CJ\aJmHsHhrNhdvCJaJhrNhC$fCJaJmHsHhrNh:CJaJmHsHhrNhC$f5CJ\aJhrNhC$fCJaJhrNh:CJaJhrNh2J|CJaJ 5҇ "@bxЈшRghijgdzAz 7$8$H$]gd+X 7$8$H$gdC$f 7$8$H$gd# 7$8$H$`gdC$f7]^7gde<[ %&13{|މ*bgkNJ׊)+,-Oȋ ȹȱȹȹӈӈ}ӈodӈӈhrNhrCJaJhrNhr5CJ\aJhrNh#CJaJhrNhC$f5CJ\aJhe<[5CJZ\aJo(he<[CJZ_H,aJo(he<[CJaJhrNhzAzB*CJaJphhrNhzAzCJaJhrNhC$fCJaJ *hrNhC$fCJaJhrNhriCJaJhrNh#ACJaJ'jk؊يPQɋʋ4^dh7$8$H$`gde<[ & F dh7$8$H$gde<[ & F 7$8$H$gd# 7$8$H$`gdC$f 7$8$H$gdC$f4H\ˌ֌",-GJRWak|}䫣vj_W_WhCJaJhh#CJaJ *hh#CJaJhb3hC$fCJaJhb3CJ_H,aJhb3CJZ_H,aJo(hb3hb3CJaJhb3CJaJhrNhC$fB* CJaJph *hrNhC$fCJaJhrNh#CJaJhe<[CJaJhrNhC$fCJaJhrNhC$f5CJ\aJhrNhdv5CJ\aJʌˌ}@ABGH 7$8$H$gdV 7$8$H$gd#A 7$8$H$`gd 7$8$H$^` gd 7$8$H$`gdb3 7$8$H$`gdC$f 7$8$H$gdC$f & F 7$8$H$gd# dh7$8$H$gde<[ȍ?@ABM&9EHWϽqcqcXcG! *hrNhc56CJ]_H,aJh~5CJ\aJhrNh#A5CJ\aJ"hrNh#A5CJ\^J_H,aJhrNh#ACJ^JaJ *hrNh#ACJaJ#hrNh5B* CJ\aJphh5B* CJ\aJph#hhC$f5B* CJ\aJphhhCJaJhh#CJaJhb3CJaJhCJaJhhCJaJWm{|ۏ܏örfRrErf9hrNh&>*CJaJhrNhI@0JCJaJ&j+hrNhI@>*CJUaJhrNhI@>*CJaJ jhrNhI@>*CJUaJhrNhI@CJaJhrNhI@B*CJaJphhrNhI@5CJ\aJh"5CJ\aJhrN6CJ]_H,aJhdr6CJ]_H,aJhrNhV 6CJ]_H,aJhrNhNE6CJ]_H,aJhrNhc56CJ]_H,aJ܏'$ & FG1$7$8$H$]G^`a$gdR$ & F1$7$8$H$^`a$gdh4$1$7$8$H$^a$gdv$1$7$8$H$^a$gdh4 $7$8$H$a$gdI@ $^a$gdI@ &', !"#$%νrrrpcrULh1>*CJaJhrNhC5CJ\aJhrNhRCJ_H,aJUhrNh&CJZ_H,aJhrNhCCJ_H,aJhrNh&CJ_H,aJhrNh&5CJ\_H,aJ$hrNh&5>*CJZ\_H,aJ!hrNh&5>*CJ\_H,aJ!hrNhC5>*CJ\_H,aJhrNh(CJ_H,aJh"CJ_H,aJhrNCJ_H,aJssible Spongiform Encephalopathy.     Explanatory Guidance for CTD submission PAGE   PAGE \* MERGEFORMAT - 5 - #$%'(*+-.01Z[def$a$ &`#$gdgJ8^gd$ $7$8$H$a$gdI@ G]G^gdR & FG1$7$8$H$]G^`gdR%&()+,./1=EZ[\bcdfg~h1>*CJaJh7[h6HhvmHnHuhvhv^JmHnHsHu hv0Jjhv0JUhv5B* CJ\aJphI}#h2hv5B* CJ\aJphI}hvjhvU $7$8$H$a$gdI@090+p8,p8-p8.p81h0P/R 48586878:p)q. A!"S#$% Dd  l 0  # A"EcLӯ+!jKT!D@=cLӯ+!jKTQ-xxeP\MK`pwܝ !$xpݝ -Cp ].kSyj^{>]}VW9ppK~@ I)IP$Gz!/ P!^&p8/\_K`$_G=?2~`L`EC/?|do?yF7Pak{HF~R+?~?_}?Qy  &^o?<,bJ; 2Nx pN2ʱ7/D 1%1&s2UW<^Vܽ \8c@0 hV$4 Q2!*j y ¶"vJ0[W OػWq6QQEJ9 KTrB&A;O㤿]ciD?y?{~΀PVB~0MHu^g3۵Įv玖~jvY?C8PCYHއD9Jn\f$6y⅐xZDCq 4me0dig D(+Ye,}y>i]l]Iqݷ]آys>y- huaYxsGd`r^qQ b$Iڃz2">#dxԪmL.Z@3[CT;Mv]}& ̺&M7cނYua1qPK+Hpɞ94L#qؠ 5;r7̑P}RLl(TB*eqk`7h, kDV' 1G[Rز2 ,'#,(`pA&8JUQȬMt-t(D\$wsF9NAy%K"C4BT\r5(shKЄ=&fg$lj^^'W u4iK?#K/;ኔ^R4cL$йFGv0&XKJHMۜUj?=V$[C  ar`p@|UEºb^ް\Ӵ5(*%k5@"Vҡs#e&Ƽ/fO%ڑ?8IS|*}Oz}?B XAyedFvGu3y NʉմRZ_V)c W`B,"&Wy܍-d!y'̥DXsSL!YX (im"պʙ:ht՗ip7nG#-88"}I =-H( X!6߰"Y kfΟϙDTCd2/{G%Lz-Lλ8B6B͐,}y'a=m59k^g)1 GҜpvoiMk#T&H!x>.nf j4BK0BļuJho&9t$@尩 =bIk(W2#/RjJ&R'0amA>tc%&xO' b]^ 9sUBe {7߭9ߡ}ZOyFQ.V>V'MXBX 螂KV{ǩc/LP}#ۦg.'aǻ]Qz-&ْ#x~)볹.\l_)H>pfn MzoS/ хiRM®W{H6^-JR;e׵ k:݅-!n~.xѧfƆp?hh&b:Vh$z}!ڂ:-P{dx j3m*_R[NohT[ͪ2#=ĻԬMJ!.'9Y+;څ8M!W=fCUB #U>gs)EyO]f%q90G`$%v5n%|.4_,j;Λu K ϴ }C?U*8%"ٓ )6F# o0bc#5ÎD'o8]ل 1n^se Q5#4hzEEͱUsKG/-{h,MIHOm0m1ɐ6Tҥ~d;Xm]&2#^*ٽJUІgTv>Lg9sÓ4΅9e?),ΦyAbBHPtM=r%Z>5f:縠vǟNt~OWPMʠYAkm=ͥV4zNٷJX-橀%CYOHc?6z6Xe@x+Fj~#L՝qo=bX Q:*V4ϩ"sޯanaR(l~.CIoU~'474-Rkp#I+,#q 'H^Gq^=,Y+^+%v-#]k&\5eHmX`tA\K(HrA8|04m>_/ k{1[M_iƯbېBJ;X%N7 <-:VّesC_^A\[EcJͲK*.L(ej6[G>xɉ[k*"OV,QT1G(]ܘ n֠GH7rsk $8#s$- #L}Y?Q!F}rAЮRlŅxȂy͓O?'WIE{B;rˬWFN2g>^UYTFco\.A?|ӖN8 m3bm 8VW:+8_l2)Qn;)U /6Қ&˂(j~`;߭"j>_&_WWQ6S0OS-nn:.X0[[ZY )z$g hxJOeR-z3tNw$q aRlaT'SĆ_ݹioIgxTНcs *#o"|$=ݺ+Yʤa}|A H'T0$Wb[iRWd;rFi`8lٻ_:v#\eC]9Ψ2RS!+P-8VO(gGwgk&G.7~mn%8B@KT`ǢHNHWڃZohB QLu!X۴q^$5Gq'](yo gpkaX+J>$f*ç{WXWB*(Cas$é{=5lj]"=*1i,5" y"{kogc A-Ÿ4'nLhw]}3V*]xwD>M׆E"+,k#R4wzjxsŸPNtYuqNKopV"btD\\mvqZg@\L]s [x>'/BgS̐d| .b2C#u5CPL^9SQHdYgCD҅'n'վZ`0=;vL4Ռ2^Xw)DF嗛-kBͷ@2j[!h3% Ż]P``>:p>Cӆ~ Rxk֥B?J(3v6Uҽ~[yT֖_h!ga g{ d/ `d0 +8h1߯k9J A&%F+r+GO}"jsW4 ςp*K3KkXQB^)] *Q@Sad}śdT6'K=,ɡFYo1xO׺ef1?m|sc[4[״0C壶;.|+[ Y{PoG۵ciG<,ڕ.)̻7viy<5ΛDH5X Mn/gtF.v1,E\YgI sBFGeD,9EMIWܛ5zU|t V#P=HڡkILuZ8-/;8ÝKk|R;B5MB(8u?D2IoݘYEZLSI;fvګwUV<$ 3. յ 5g8 %k#=U3sErxYV*n两psfCm✾kyR 8cu*!~U]+RlTiKmQt~:5 UA73<kJ0:$QZxnuEC|Uj2%N* L ((U9?W1+Aw(@)법.';٘薥>8RDcG3ރI(32'/ vNqC˰W߅'0tSboM/]he 3l11<d1٨QN&[)i%%yjV'R '/zr|'.}ףIA;Ṷ1B*{ @^ z7c%&|G |w:$*X#$rMĽ3` Y$@>&ɇzڧ5 )>(y$q.{ jZv #O;IǺE#p"gLi?lh}'wSRa pEFX{eިN|pSNòu?fݲ^Tg.mJ0]ڈcy*11k_3M&'oaOb=r=Y1V %os#7-͹Iɽ4ĜE 56dHp7wmrM^a n*` SHK3tr5:yMSukSģO_BVH3cj| 孚߆TD!Kk -ʭʛ *QoQ/ؙ*԰q^KNJjSO'oednx / (]V8\y?S"w㓅qS͂Ҽo Hk}VN ^xbb.7=o\yMUy! ^|uN([۷(ysL뙵3㠱Z"]r#v-HpJI"mBa*g:"1'eKvYu#Sj飗q붼c:UpYh0Mٽ6SIO6+ 9c35 Enw[]Ě>2zȺyHZxӳqBc%kg^y$PB{NpG%m `~ ޛ ~ڏDVS ^KPssʥ_kdm1|Eks$*)6:'ڦ|'/g*pT4:•HeZTN(hmGg?Ix'RУ/dߔU"0jjt u؇W'oodP;JUADB \/hc}'ׯMp2ߕ;cM'7B̥"1·7bi\ՃBZ~}>֩)ŹM`q52"v4F1AS8RE\ˀB^_5 :?;iPk`yPn BW1(02xqXhY6 x*VCsWOͣ?p@Q1d")_/bcjdž h?NZV |HWlKU*[郔rvEC@7^'"+ahw n7(TXc~ظ21&pQOZ(Do] lv\a1D 4$O-Hot]5jm0Tlu`z ,bVvOEDg+X_j[LrJ u~5 ^Md02+=!f 3CE_ekiDX>LZ[78q`RYD+Qj:p8aE2[y0`Y~"HMw 8m[ âT|%k+K1a.Q%Ǟ& g}^d4_ї4-f;1odEHLFN*9un|pⅼrXCV^=>IB!BiPO.hN- XVun$#%|j_SaI,S&R}1MpgIN5;uC_n"]5ʌ"I9\gQ8" SR mM 䊼RarYaj!` CQD‡G s› c H4" $(&%ż=E0qV.flt.ۼ˺l6.^ms/̋|罤7(Il]>Ʀ)NR3׬;1 n(cc4x;bO#AOʷ_K>4M=kB|FRIuF`Z=OJ7P*-+x`,gQTJ/c6H5\ɔ$MūmۤwY??{.HZ/M.¡:vfq3y]v:i5(}k[c<{  >lXەG-d|q;VdA1iTDni+Y\YcbM|*U}oLtL"Ltg]4uWyϩbDa#89q $:BW:%[]^t j-pdz僱zs-ORxTU{39`jNj!b V Gn$Uo ۜmmk,N'@wմnR&eΰP%[0}gNm8Z}^ηbŪj۳os7|PJ0xpׄY/ɢ~ -7m~&C ruS z`eo)G| ǂ*:Y>f 33|0T-&Dd`-$$^0[A_b0\XQusq wfyCF J)[{O-vZ|]9jyDcMeaq&* y6l %pQ4"5T2+nLC\KY^:e[CX\TE~ (33b+gBj>*/FJ;&K1|wV1R%K"#u6'ǒ4ʨD=Niv,5?;S$hY^tU&ajѴXw2؆JN1a?"U2$!LKq!bl!io6CM܎x+wh9/ ثyh

\| LWu2Ͼ݋ mm;XpNTQT }k &]E˞X-ȿB"K|%I|$ `ɲk27oȟyg`,)[B/k,ʇ_(i?eԇK2U{D_pqe#4[sEL^:~gxn3.ymCfk"D-#:X;qȞܓwN=?_amɞTʿmݴ#2ؿ&zɫdH'Fm6i6odgvFcfG3tn)s(Qٸcz"m)E. 1њ;#c\3]ڰ҂^~H IRB;oV= k^%K2)iak LA"HXS<*tPR!q`?zHt|އĻ4S}n 7N0juUܗ|XUjח2y:ܣ?B(8{/ع$26԰!Rj޸>:ʨw5-O2J ګ+"[` |ʝI-Fg`q@Z`=vLex#@*v?zW+yɄlQhkZRk& nދqD#}-Y$Rˢ>τc(8(4GۘeS[w7-o3t$IUw[fLb@q% 7㩸"%u'`&=yᡗ|O$Arv r5aWFLfTo?K7i_g: sC 6dIA =cx8yH&;+4%5~8r,W"ܢخD"0nBda .ү6 3ٍAlD7dX$uL?."9GX`weOKÀH%QakS%~Zml}qӎ;ºB G=;7Vo%AQ'SH:GY?MΊO05(ʨgc9xcPS1|g;v˃2ںgg[W}OX+qR;~ .;K#CەH乳cIC{r=>]' },2;37 La_(FC\h% #c+ LR?dW )0MЗ7ǽEE"G (u?lعz2RSֶW?Ź.ini'bj$pzTv?Webp)k\N -шY4NeD,ĵP]6\%$pRqJ3d- 3'fa lpx{f“f.@pi`|4iaUKԀ_i!?Ai6*{%ɧj"8#0(LʇN oM)gb #Xe~L/hq}[Ff1Y7%8#R Džk_P(;gl{5_5Vٮ58xzYOHLZ5p<:SE$j>Y>NwN yX:F{2y)Xһ QVnʼ%B,`A)x%zv(,"WxEmfr2j$Ht!Y3tssMM+뫴S5MI3BǺҸ>QΠRXuI~! zS&Mz9$P)~uC߱\2[YxT@ ER݀itՆ@wk ^vjMǫKExº :D^9+3X_[xQ&'c(и6[oR/c8^|7kJj{o[ϱ96-#h9DZ%7rz9:F.Ava_A`Ď2ꁴGhhY9b3Ęr?l|(kVbL.W6:ғ}z5pP<_fGiv9|uSRrǺz*[alʥ(隣ڴUB#^X6@L lVu5 H Vά,0LԦ;3|*[e(r+'^dKϨ[GRwж[5Y&FfFl!Kw,*ٻ<.BrG#Xsao5H2}:gAD"ku?83?ؽPcAY d܁k@)204A`PJ*98`rYzl #%y XWuEuV~LQJ#9& R(bnjQ;n-ᨺM[?䏞mr6+.Ũ]eǹ~-lΉWl$B9IjT}iVO˵C'[vuo<~v˦2jSᲩ/;V{NY,N9)O& -O#ws0}K~y/jj5ZƤQn>XSX򓓕OWl$?q8O20[@X{:fqc^vQҧm\R0Pc"IGnk#{K>XGt"mels ˠciÅ?^&śۏ.t:|mt5eOZ;P+_էEU2h6o|JG f8 .aʹNB߱wbD_ b$,L1OuO a$@G: P:y-No^'{ݗ y^RhQƂ2v+ӱsX|w H:m{, ztop0G߅S?iZEn$'J힖)ĠTlC 6cܷ-@Iޛ<!k1??nʓc/v _9?ծRf&ԷQ5MH4L` oRTW,5!yJ,%<E j.l(AG8-\6(VċU Md#lv]\oy-YwF}ZS( +m|cjF#7?k̭j,_xpM{skw7$žPh9// ] J)ox5uLٶm.土Li%d_E(oere$\NDI$ 9LKg<%SCBK̇\tF@U IH4f?y##gjH)]ĸn~='`D q\"Q$x|41cYF8TGat!eMWuv>8N3U-)O'h)1xfIO ͉a/ΜhzB)hjkb~B}өiϚ}xid#)Yu W k`=R BrfhӴ޾]iXQ2q Q-v3rOF @ ]U)"Xn2tϢuk 6LflT5$szkj **eY (y[L?ऻbK% 11KWi78iMy\0-\[tO=>hFKWcQw5S_[L~_ڥ+ /8tte`uP}(Ϳjq%N~Q ۳5,12r^?GcwnUGAa-Kgήmnf#94K>Cj ,.˜yċd^/P\wxqta(iXᒎGz">7|h9mh&|CMc: 1[囌9hǻ Mτ0S%wEhoC:<cod,5j`H;~*-4^ {07VHV7T7CQ@>p8OOhZ¸ű3󯕛)<ܧOy>DGҞ&3{A(i6C9MJy֝ r*@3\+9=di+W(Qu]5Iƪ=7^>Ȗ_:{"s[' <*MI}Boix0oEP:|1o(033f1+6AĮz}+w bƒp6n~ȷ+EL+? \ĺ q) ߚIxgP]zOŅ4XOAD?ԗcnCi&&(jTyD%Jyjb_G R$IdiOtJhk2^tpQjLïO1DY`SɁbIYT+]~1r_1<(tcUT-;p}f)\g7!(B/)Vy>~=%2j fӻ&Gބ9$nLjtH.XZVC@%EZnn8Op.3`.晋yT'=o疊hMqrRb^̀hDp4t4'q3&^0pUM'| ҚXA\W(9[Ɩl@Pȧ]N_A^Tժ2/(= >`2>t;B^uNqIAHuc<.|68:n WF'( Uy.ΐXL>;95W}i_F.8w`Ά9!wˍ9N#\|LW+']}UM#9-k;kOQ =ɂW-64ǎ wX2m;# ߂>v|$$ 9,cr [m{W8zJ?A_V^ÞlD `AiOJX3|aFHEt4viO8Yk@"01Gq}OP|`է 2>ճ[LS$}z5Uުwb^KuGdϗ M&gL5דhB*OS&: z]ODbMBCs܍m͑jAKQ6`^K6gx~O5Bk| oßX[˪]w&/Їi!8IUNEnaT"s ϑL%j:)P[Esr_3R_]iFp/'A_7VV6ʻqƎ_Oz^ z. ~ƝcZgtB yg@' 1Ĝ*$Cay |Y-l#K^z4?B0&%!Cjr_TT i/ H yAe7ũ (c(X[eJL0A&Gaڊ.v7vVzhx=};1.qycF}[H}E; X lhrE9LQˁ?vVo/x}[֛cTl՛ٸ=Vbz.sD׹ۦ2J(r1^ @Xndq{WL [/tYme`z@1BǁgY}haT"p?ZYgK;ZoʴJ &"D6/B4IкiTWS_h/td$)aа҅%ʄLz VJUg&ӧP0>wFp0M nC> SRz({&&pIesWΐ[6Q+5O(e>Sĭ_:· k3vNH-O\(T2E= EͰDO%6 H2D`[z͎'֑Pۿ5V)CcF 'v4uBs)յJ\F>VȃэVK!#:W?SsDͫ^(g$^Խo17LHYaY[[S_!Amzk? 8&ݏ,.(DK>eb'wqY#wY蝭/zƐN_1S1kή?"?֟ !ȋN "zk' `),,qԓK*iYΛҍ y xgŖbA1mgl  xR4k)]!VrAhC[NXoc9SKxԹF:_&7Ņ^-\Q'-̋sgLsގ\Pps@{"NJQ=F4+N"D;3B@є_biE\ML; -3'-2f|集BktgܞqDņȐE::jQK.f.D?0#f7N@<6Ú,A^Hw,WM |t!QETg׹.}< ( V,RݍS[]ncjP}Lxhv O2 +P1~% 3 9I| O_|\ `[`7aDќUjt0Fpi~ghOnh(T8 '?0ϴ|5}b{R;] (,+ғ/GE]fYۯ%DʤEj:Z\]IAȴNs,7cw ~>ŦZ&'̢[OB''-TQv˶H+W GX|o!{ֶT*h{J߯`3}3@¤ڷw(S4u`(Df>RF~x jH9Ks~YV[Xb+W+p_Pat6&qf1h4ۭl7֗ۓr捅!:ele aCH©m9_cm/ءΤF{3s'tI7XzsoŨk-?%, .*;|h3&_Jj$~Qgl̽d1̙Դ&~| * q{'yk;Q{]f:Fy'N#t:|E>,~ũ?1lؗ B%CT+1|V{}ޱqgfl*̦xHu20)$_Y#ʥFY)'g/!#CN\e;ЕzՌ8{7+Wn*K}}q}>'n| N_>A-t1r0Qbi)GZZQ&tDsE6E평]qoo\qGԾf1{Wʲw!R1Xtt@wJ hZzef-yg")9) sSsuT?m* .yϳxylk4K\cf2UU.@C-yӗ̖:!j8DNjgWU}]WD\^X¿#QRRP+x@`x3es[7٣5\{w6o+/z/g?? 'ۓV)I ]Ɯjfv__ .o4[7u]6CuO|S mn} ;.95!qjR#8meuS',©GBOf5UoْW2?0ߵ)C]$V}.7}'nRq3o7! `V lB֤bCoeW<˕|}_%&'+ǕP tg9UBQw<=8R^eӧl#sl8r\Q5)id2bWJ{R4 ?.<or b5$9l 5)PR.'f+;LYX\ l`= HMe~k yfe uSD>K-θf '˃ȗbo^g7-oQLE ,FWJGe &~ϖgx6&AqG?N OvosHs#@ߔUzn80q7bՃռ;*$2o;W"ff:~`0s ^BvqXNKb ly'uW4)SzN͹~r:k\TQOpmIeqIR*ġӓ7DZ4Äi}usK'I?$hw;#p8 W4n2hŬr7&a~Xf7”%MD$'SLz<_sAhL6&fP/ L᪊]J͎"ߢ0s k俴&8/-:Q'&E8+M;D Y O8benk nAnlaj,yy !=i$tS_B'j2~M/P0clls$eOR&tq{ VL!.ʧ/1W4 tc`fI\!G},bS&ڥb}OeФFNKf;(廑ř0M۔2}́a?r~ dX_V3,5W ~/ߒ6:CT$Uty pS}w/WjΦ Jj3?z$7bN{Ȅa/E1 l)}l"a 6W b5|R@ൔe?zJ\QxR -GjN)ԛ cLYP^{gvz?/jL81~]Z h}3!1nS|MNrʈzL|`*)%"L –.E 隀+cB+'z8u6,k p9se*뚢(hIqj}rM@H dp珅m]o--b mwi$ @ӘO&jBzW{ f%< A)2.>SVJdךx6YgY756ZjUiiFE*+q&{ξX+ˍ1N0Q Vd2})#(%Q@8'ihSq3PVnbeh!S2>_(<} SAZǖtƁd/u<ٻ`!O$Tiϗwne x*wM5ˆx=|F91+XF-(8 kv egy [;ŘzvNvH'ȳ2ik'v[&6nftd918f0VSz-}40(HLN(du*@lOg_fH,>дX!M%P_m򊨮ktcƕ,n;jʇ+5R,H;pr Os^"cYԭJA]>ń_5EԎ($4v4ħQ{1`2%ZM<-DWTs^B+(C+ hZ?& {ũ 1ԋ8 N44& A ?,r~HTb=jzn2+u0S/6˺Cc]4窾WfyDLJxt=(d(=Di{!{:Jɍh@ @O)rDMCu3:V Աx~W4'RɄs%[dsh[H:~K*f*gǐҍ̾F8nC6{aCw;ŷ$N"΀E9=C]c1TA,xtॽ6;W@IFv LfV*_]1 0zI^UQ`Zd9 * (رnK.jIeI<>=GӷTwЧqRwn2 EEYq)Gj#0Lm_t>PoG')e ϝyEjOՏ ' I׷Rx UMؤU"O^gǽys|&lY:hҀ JW?5k7wTRV3"kB`]o 8kޙ.PN'#sR`Eτ>A4u,. _")g D XɄazMV E8߹ ֛I)zIG_Y##XHλI~_rfނIc>[>Ձ߰KJFcn'lMRjB $jR,"h ʢ'aQv@Qi+EKT.,ҦT V&)YϹs',]̙YΝ9s&:_;xn2W".{c_݅ _ͬhn)\ۭЙ~/v KZq n[K;m5OwebkK1vs~Cn=uZqt]EqT7ڗ|U&O3-<ޛzߴEk}պ_et\57Ns2)'M_$pݼZՓ||;J^kKWmΛ;s`b5ׁLW?X0jo ToT=džo/]^7NyŰhPuov޺hg׼ [V|sϡ:Eno;G\-.Y#ZΫ]G oetT})iœ)C~mcR:&f7RwE';e}>pPYii˟~R#zxn.̙j˛7xlu|_1+n,ăwNܹ','e>U>0;l˚y>Y_IO_e;XFw}dN~n-_{MqȨӼyQmiP`1fzޚQ1ˆ~葾wǮآ{yd-W >Yr%ջy~$͏Gn:bPe9\;-&淪lom`*w8nzĿּ"sIsR%G၎O<-i/M{V*=^6޻oofeN7?Vkz~;%dQccV@ĽcqS2{fV"o}ޝOD-(-εl}5K/7/96U3u |ѷmW.];*Y}\u^PiFmn w;֜T~߷ƭ.rny˯}{v²C旓F~:Wt;V=MRtNygcU3}cяg˒<4m)ޒVs?Ξ>?86kEy͓H=*{쫏>[.W=pft]cE?jRިY}sל0=[}l1Ƨq؇n|e׽g˛WxZ?#(uaS~ǫ^ߚFӣ+{gm3mbT.<;31Щ'zX}34Mʫ'7op&o?jy'S-ٜ/]*otwt]VEev臋؛s6kLv?V5/^0rw=_ذ ώ-ۦonU߲ukNߵn/I: |=zc??}*NJoL§[~g^5k2Ks ]5s+%>:lf&v?'jԤw5fLM< k:y||7nrR@Elm۵KdEqˉ^wL#wt^o͇Ff~._{YcGe@‡̦f O'ns_(.<у/> '8lvVu8\`,tws]κ6=7o ߛf2ɟ[4=T5zv:0ڝ\l{ޙRZĉTo]uCuN>Fѹ_AqXޖϭ*k>N:45F+w{>hg3{7 ~v+⾞|쌴w`QOF;}ܿj󒚊H_WNW2}C b1miӛTs뀌o;E?m%t&zpwsE`;1̰~4^x7 qf~Vʊ`.xtrvtӇg~6";x2._<,; +aSdzUG ZCa(RFf-wb5ȆdV|UYޝ^QMӽ]܊\{7:>uW3=a=\񓢦oMG@~'ߗOXҚK&k؛{]x- 3T;SsTژ+n fa,vvSEɘNKX/c66ēȘӰb@~6@PffLo*6Hb{? z?HJ%$&~材=0 "HBaZB#AVEE-k][huQ@)RPii^VتƄ OT=$̂S@o&9_HcƍTwky7%^j^^#ܥh)J>x4WJlqS>/qSW+ݫG(oxxؤ5-)J6[NfPScQ_J_rngxǂ|h |u`'6?z&j{a-V6A:2 0gA$%N&(< |@A90f5kXCJZS|D_-7m3RQ`]%g ,L#j0\~>4ڍ9n#@ S30%v 36K Kap"1L>E;kdKRrz;k/2ʺēN\YPUʍYa漨IYPj`&9GH_bfOwru\9!>1SR|װ&^BģD'¤vQv2xN6 +g')Ro͹p>84`a[ |lϢ0Mp ᅡԮA`bwls`>IiN xH2;6i=)Hm1fm /FT8g3A缦m1iQHdJGdRN)iԟ}{!uko`ipdN9Lb5HXwc9  /B`e-+ؗFgŋTR 4^ذ;q< >KHOᵳ D'ԍU d3i. ]% XGM` (ixal0m@@׎"~ \z~~$?;I`/A`?ײA`]&}8/`X.L;Gڮ TYf@/|G$>9Xeq pL ӌ%~c'bs-Eq%| gL ["*I\ 0f5-ߗqYlߤ&A@NA;|H]V{R/w|joI`9osu=oqVl-ԏit(^QOݗz(d@C.O9ԏ{PXfYE!|ha1j7E K(pQ+1?&[`.tV EB i3&!ܥ|C ?"EK)dd¢V!cS;etwJ=l3XƟ:W r;uId'uogԎoJܲ>R[+i_#' cm|X`-Vyq}0TJaRf'䰠\vr|w2L;kF̱_֟;ۛk֌ h4NőyY>GBS X]nAmة*䃵HAKfe5f8Y=GD NVػoFBbP+ nNf,C<̥͇oxss*80P`̃%iZiͺ&J [ضu%Q^u ChZiSh@FU^A,vh<[ƭvAY2&\P`98`5T\ ޘ~3Qf#yhxs+ڗ\P; 2#M4ȵqZ. \kj#h!pIhcҗ \1(]jEB[tľV*\R!$4lxU#qBF45 I-зKciֹJ-*H_UtX2(C 9A^?7ԻL Fe0'd(Sa'Fp(һ5M0ĥЁ!ub!$/cPˉr݀YtR\IŎF hAH֣QL:)jS˜AJ-9ؔY?GauʥR}+I_ x钒8$&?n. [_5 qV{2Vʢ˄qP݄>4E5=[mѕE$ջaC5A]@1?1xR/UPrqxJ`x9BeiйT*3;[to.dٞUǛ?Ͷ3#0b?HdqBҹ vtCKZS;OaUh-oKcEKGB[3i+fݐXqcM0>@?vc2xx8 Pd"­F^oL6f F˦К X*uOV+ȁZ`'?̀U`qi*T&{8M bWRk5xUT,Pr05Q0lXj4FE5SAt$ 'ဏ!>(J,u4)Pa.# ;{0|:;nV'74ј`c~0j@Bc$ 3:BC#7°WCnBi4C=כ)<ǐ'N3o74.yoHZH.rSO& ?&tA{~ZZt S{=>UhCmeØ_oc/_G]P. O1|!$`P˫ :怼])er`o"BÅ2 7 o dųviB8C"AE3>%ꫠW *v蟏Ѝ<$թY$/" e (=[FMe7Yz쳐x) sb6^JC ϊkx%=eM!z F &1WiXPQ~USS*kc(߳O^`4p=_ cp-RWd~̴ܴ_F pU r I ݮRջFȒ^ @W=~R&20=(A8[AqY$+K6I:$v1j|P.` jH˃qTS Tf$6: ,sCʘd,ņ2^\*!$B0 /lݡBJ0XXvZqEeЇ(Iq T1 nX4 8П'S"(ӉT⯀B/%m@j2qA* dm܄mQd6Flb.@tu18'P~Y TlS tqC+8ނ̤AMBCG9''7S=gAI 56xfguEld*C%38&ę :8 *l,ߔ|)'^}KnM+HBNKʄgl,kPԠjG-:/9Y" y_ ژ0f(̸Lniߢ'~fm}zH *g ,.ͷEg x)FYA(QcӖ3BG? ԝi+}o.1mtA+% igXIyEYy<ƇY[T O} N,Μ!N16|9[ MBLz8S'"TUPya`ZqXxFW8S`㖫BVc|K27Û{$>?" 不 abi4FeЦiCXmhZm=Fe|i Q\s=wWMr QCMggkwPMuѦR[&-a%&^F 6LVW4)D]zFr Z^DN+g Ƴ[jyl[BQnzi ]Oǖ =" K8_Ww0F b&@4C>dM4= a\P= S*`mgnpՕF] <%N%@WN4dy7Eڠ`sI_pO6O;CЇ\ͩ& iq֣AAH ɨEN.)Fj ,KS :P >`awA(9I)L&ԮKGU-z.\ B%,-4AD!'@9YooدT K/~% w0fpsJ/m>q½E7Xi5l gf >ȵ>."Qr[B.ϥM&hpPz6r fwZ#_F $ * 1.uuxe8^W/R8]`4 6bb&\7ͧߗ6dZOÿΟftTFI5#\M)|j7BA\_p2}ihoY6} "Pw8:XMxQ{ d`mo$(soD~?nc*PZ%''lF]G^P:h@'W*G>ܟ (Wl^y[\ -"C.|ip mr =Dگ6t'p#`{"bzNj^-pS׈ +dG9V>qDAuk/0qp] mP-QрJVxѓs;.VHACF8q h%ЖPwBKX6Pk(>}@1_pmNdg^-p'.a(q],n0ŷ7&mބ HֲZER<|mh(YRihJ ߘAi1Nj#;J*ueFM:<Zu4.mpÞ5ooomTZ])pcxHx(W&ǂwW(t5$AN?^\?!&\:[/By{a\M1N#- _u1(Tmv {K;JbIXs{ |}/{&Z'xL%ЦiwUCn`@VACǩr1i9l D<E3=6mh9Y s1si 8:zVo%W~\uyA}.w4=-\01Ԏ0R) 6>tW~[]ḊM$HĥyGptweP{n5q h Icp;/ߠ,-y !W 5Sp׍5EBw.6ȓ'SP_VZbZ+ w=wGsLQ<\8m0,y1{qMۅ)RE̛tX5fc2lepKHJCJteEхf P򋤁[*U4JIWpJaq N!{F2VRIŕ*Q20v0Y-3g=ЂC㠡AɋPs Bk0tWtQ_/Wр,);>ok(mP^ZϧR %s%Qspdy6'wόO<\  ~]ۼ UKzI؇ Bh3iGFWLX2C;18%r>LІW&MZ~U xMVWMR7ϣ_|.wjADzN(V?\N+(M/ƺNp G0nmPf&ˀ]+`B Th`oXo)wv6Q 0ڐؙTAo`\jy]zp^fck\S< 6 tm`bk5Y =ƯM\Du}e ]7mSrb./@hC/8ru36ޏA~ N[`NL;[P]m9gz;/ǣV' 9cZe[k  ܖ/㏧iCB ~`.R#}uE&JӔC3pe[6hʑDgLSPGd X4 xX?Q&aChӰDBh}$Vm ġq#c Nv&Nz`={ZP+6CčaD! +`(7-`m-Tȋ!o u"_vMy׍8 #N*T^(aWLy3 hPUˇjgbV#Ʋ0P4 |Bԧ hS0mM8kܸ4.~I=Bp׸q#i\z6`qFhӸ 'm^ƍЦqNڄƍM7# {7Bo8Gh7n6pR&5nmM8kܸ4.~I=Bp׸q#i\z6`qFhӸ 'm^ƍЦqN'Awi$oJ?@r => z4c5т[ޓi\p9KTeSX2QI?؁=ݚShuƛKuKxkX7m\) -p~»/u/ aqC?!νxO9@@uƛ<uP p< ~ݴC` ӊԅ99] V#oPOr돁6ڲZut S 7g;&x #Yש2yJ,g^IV ;ѐ-AX mku$ЇR`w[B.#Qʰ3 !`{蟧O50v _Hٟ](Th2twCTK?Kg5`(xc>ai}w+7a3.Sz%'XhXAKg>>l@h -Ƿ`w2z@}k<[ڣC+@^a3 {42Sp'Oym?+B`N)Ѵ+MI8;t9Rll~ȀVjX 6#Ǚh8&XPJ @;`s:=@{jde|JZ>wזPr=url0s {, z?ʍvE8C-r #\/Dj岢?  E+)ʱA#ՑWֳԆ7>F*~)Y2njƕ?9N|)F~Xبݍ&҈CL~??dA4 l}cr` i~5p48~Hk!qAF r.Q1ljhHºY|ďbe\HPt_ bdL2-ͼ䅾W{RtЋri= ^hG}?\.60K[g3~N5u|,ڸ -s&6`UA`ȏKW.*`! b5W|DU} >4>g=G @[AF{=zF Tfꩄ Jڱ9VVV,V% E!g5$PPnZ=XixB:cl0/\j`F |}))FЁ=٣#uw*WZ%r)__fmNzUQglPF; Z@-H!@~9oPLR )Ց6mdZB班b\nS=`3, +|0.ǀf KE0@K7ͥ; `Gh e#Rܥ38Wz^bTς z#rP}`ZM h}4,kb~Ej6GX=g@(}7|; V^ܡ~8 I!:h';4|g&2ߺ6R_]>A^by.Ń翪15<6L+0J 1ZZo!/K,/\,7KOXJtВ.pE-H(19/#o\ʺh&ۀb_Hv%|y bTJ~߁ h >~_R쓬?_+,ł,qؔ.fZ@ڵXفnO? c/K[@ !h㸶(cwH}Br/RG~MoQ(8|b`pF5U-M`36YhϵXs}l>)2i6w8>uw<2PCzc{<&D3ho/}k`~+fpx@k/R9e@}*9S69W% r7᪔Rzkk`3 -xkHw)]cҧYK1\?~l*f}N] 0/p3Hi"E>>ū_嵃A. ?kyĆ|]}xAZ=5Zp-&kѾjX'7~L_MИT.4Q]گg5k@(!*#?uMM5a=))q"ks'Yp6Y߮ dphA\ypB`#"Xa^Wq;kx.&ۻ*:ȩ\IeYIYkeZYV*PdD>A,0_M$DDDymp~x?"Q{<" 1SC rgq=6m5™ 1{' g@HC hcJ6#T[t8InWіVdsY5yxpN%kT$'kL|)VZm*<X 3~|w<3dl &Nf7Lmzd'ɲ:ͯ*jN:;ysr|~D\28: \ת:^1"2'@>$o0plN 7w9XWZep,[~|6^n\R4YA+'ygs/N0x˜߾^rm]-%juwͷ =fQI!Vo4z}fBKZ[JY#_CIѠ (&|ەĜZSUK^r*NM>u|ggk~W=Q۵DYQ!HWƴr*~;T7Z8W/# )~L]CyL間Yn*{zDd(J<-MӉtyS}4tΞ=)o4_t|9HG\-x7111ejk|])+ @qjL%YG4 M/6fqvKve CYm= Wf[}͵:{tjNZ8rRo9j;o&hTp$ћ2,. II|[4#fD)=o"$'v[ӟuPk#E/ˇ b8!̅)"=6>'D@t5d͊,oղ&;Î'57XVamy,ʥ:4L8vfnQ}xZ/|_4}oS[rCPȑM A*1r4(Lx;opu=I^ҷOf h̚r]xY>Y~{Q5)e;s䜗;'o퉣unΰ{o9ݚ=j` ~)H.)8&Bof{_*%=mw`},{6s4:s}SߐNih"&f$`RgLx ugϬپ}JJ:n\t5>uvHM[)$ea-UI2Wg"O9<.\OPAɫ@,vQG@`=Az\Mwω[{t̶gy4 ax=ȧ*b ٵ3765(FonQ( бPA6[dt8O er+x/dr_-Wyר^2lhW4&Mt/Zl`ٮFل^y&N^7+Rfn)缝.7,cˣ29}٭Sj.R$V8Rw|ӣC҄ъ*cj&ц7 Ir5FIXud%mC uxxkU&ۚlY]U5Y{)K1Y^'vt"li⓱͢yyG 7j ~5%[6Q?ya'Fr$u-6ep۽#L4ͬO1KV49i3(}kו<9 (т+s.M;ℨ6o TLL#ѰiԹׇCo=wʹdGnҨ}HfkyN0;[Se,,2eƇNbJ$w$5>7}e;ahV=ږ~-ͽ1-2ByX;&twdqQ[YdSYUF1zQ6iA)KpB@.iTj@!: >nAOƝ簭9h#ZZM0*;*:褌b@<:]n6:w+;ӭɻI'/?+KMEȵ1 '_To$qoހy[G.3?*'ʛP.ҼWwTnӆKTDXGku Þ{7\ˇ7t Ts=2UepA,J ;_H,v8q$ ~S>Jm, $ZٳoIկ'339<ݤ7Mj㢼dVow7xIM=LpCF<9 6H$?LOJܝcuo8z`MFd>vjb2CFuuQ(6#LpMtqmsG21N5^WlAؾ/Te(?",H> E$]B+kéqGYjcɑJ+$+ddX:s븕HYj5^BJ1g oM<{׾?Wr,P@ go@>VU''z 5l;i{D+^_g~&+cR^klWUy]QϑzTWVͺqF{ ԮO {/e())ṠV* '/lay^f#KR\fz2EUSeku'q6nO(Ms#9tJi Oh ^dC]d(\it5/ƼܗcwT-_NUY#FGwK9ԭ6QnhoNb)1 *,at@5%wO=wS ?~-R>Cq'ԾBȽzF<0{nb!QV]LاFw@^$NoOdSVV,掌+%`8}5VLk|1ζNmnjCP /. -`x-)cjPiѮ3C5Uf,5sOD[{3JمOpcEWJKNk(gKM)7{k0;ř0Ӈc!.wL_aη Ox29>pgxbbNcp>OrEl?Js 3ɺ Uv4HRmAw7>(r$>)q6Ե|<"5.ҌK(z9\0㶝{b܉%ma* [2)B䎼EmY#$`!*r^vWQm.tA; ꜲҌu. ,z+]?E1ovRͅt؉oWNjحe:ZG岔Htev-nDZ}ѳs޿E_4-rrr mŃRGS'zJg]NJY`ɒ -x5S(7~Cզ 쓔'ߕ#dP2hV:RDj<4<<ᤲOu nj.H6?p =gP7,}9 >W6du4=w&*gEzhC΢Ac5Vz6;(͙f)Cumťqcepb.fH|Vڻ=AU7W2Wgt>rdUiGg .z&Y4i 7Fp8m`Cyd^_ܪvs=":*bL$6=ɖ9x пML`uV+HްN6 KSwuҾ {bDqrEiIpp>%%Fye/R\?jѾ#nDˁ뭟JQrd֫NgӅ#oXWG2qAkX+;5{k *Ex~[u>fϮeL>޺CPf$7hzQdlk̐}u+dGR1cnnܫ:?*RAm'OL#ûՍ*)rVf8K_3zdfSb\)94k!5QS'Io&M9-HA-Rt:n n1lF۬J{#9<*2E_1atdLWgM\|hx९C6 MJo(u2hVGF7LUӣ9iw3ܴփj3zʓc /^M:%rDmrGG7Wͭ|'4>w͖͗dz@.tZqf >]Gb/c-^Qc{0s$7oıQ{\n8˵j a MZ:+`#>r! gJ\ nVԵkB$:Dheޗ+nj|;-^@/<7T]\:P2n 2Z慶M).r b;UzPk`F.`4<a]!s/nQ駓^4;IxnCъO b0?lhr.W'dth O$'z^͘_kșEpZԍɕXN>oKJrc/^4Њu27}Y6޽.&ѱ!:6yﻍ;?!OȨ0轚=yZձr'"U !vֺ[ϕXxuN(pjzJ{n9t. DiaIyfF/IV*[3ӝ!]sxLk4X{il|UF .?槷Dثa}x)7پ[7>N11V)w1'}OT!8^^ytۉز0ZΝ vsSUgf LMFSܑܻ!|uۺVzĢ) EĮ˞}T/i%UjL5׭Ar(|NU3Wq/]${KZvA{to;eIn%تCnmg䓵U=o펨tm#u篵ѿ˴C^p:0\yK|rt~N5pUrGOwvq۶^1|BH|xñ̑' ϞJ{cޖ&c؅3*wm'w+w3ϛ+yŎ8@ӕ骺gLhṆS ۔,=BX )7 4銐n9攣{O{m1>hpTPֻZO-&_e*l`9wR'dO#5T|Ł3*|$8)\'hZoƛiFuEnzr1|Fl<L3ֺq"> vjvaV }ї]J]]EQcH wh +2Qr{} {TY霈 STq}|XD\F$RLL+ *L=}tj R at̴qcQn k!OTEK1_Ǘ˞'$E `SKkm'l_t&{[lsp# N1>Bm} a ;Mg J˾ԙzP'S-dZZݜwِ6Q0C[e8k8Ndv!٤ vo/z|~e]]G൲7O-t!ZW=di떆3m(?)8Xq,bu\:y7?^^+98r"0c:Sݧ\~(G~ux4۫F**^=m@aS.>N6}1 UH~Z25],{޶H㭑5qD [}MUB!yg݊+Cqm/=%l:,i3V@'iR}oJغv*z|H11m~vw$x;|f#MͰhfnr)9_[ZIbޯٞ"˰__sBv}#n+3?xIx5m[ =ϙM5Af߯/6oDh%[BL憿r΂SZ(u椾aq՘`)J;]}ߟ\&QB%NsI|eqUuմXv`8Lܥ'!eFf9{x4^-#̢Ҭ r ~|vAFԽNך+ܷ=KEK<73u^U|.p|GOJJn 5k0[ i[Kvn⫔lu͓ͬP9PkbIGYTm~es=JzhOӣw dl89Ҿx$Wg:/0-%˭ 0j\j$2]MG[i}OD+w埬޲/n!ş?,qK^Fp䨝.#UD]?bLXӄ>pm}] nb_b6l^[z%Ca,d3Y+WǮojS-f}Bgz~>NERLY'l`A*gxmP֦/㝲ܻY鄫3w}B1%eSn/>:~Z6DƯ.zٶw M,o2wkTdʔl-o~ӤU)œ3&bxFLfFԳͩˋ4LKnr{ur+fNI:-#+KlwH ;g;펛Vi+m]sϞ~=%}YFq`??L*,y$BVB ً'U_3un{Ll-6&A];;5LfFCW"b*֦K0[PHCF7E]w;۝[>k>6u4R+ ?}E'#eT69{w*i܊ޭ4\ū'fh#LJ<Ծ11.z\Tė9) " öZXbpí|9;1e cN@0v85]mZ14zLj2"W$4jMkaȦ䝮lFD1eCĝDV_$_[ևX `k5b Bjqʰ#hFGUDAc6rWMK]gݻb7gٍ֯U- ?ͷZ}rWم焭Ilx4#M pB%ғCب.p","њnpt6RhڧvALR9IR>5[Jn٪ǖwy8Kt\5'[ޭUX]xmCW4g4B"՟KHΟO#5]4\ɨݸ09cp])ͽړҍ.2oUW.[7bGޕ8f[Y6LŐ l ?1yyƛKon(=1|b,8xH?`ζUרy|*àd%vlϲ4kjL,V tR|',+P)V[Ne.V#]3˳==>)=ҏ&Pa/gP0G[b.5%JҹE>@q©؄ wfrh+W[ɪl|U i݃ f?ꕬcS4X8|RdHڋDǸS/N`n6 b"b4)\4B2jpT]34nɟߘ4MA8]@/SM.56ޛ?)yq=v5(A ކR]X l42CK)*;*\Ni^#wGWu2S7 _ӊkZN\ Uj{|O3bh曺g7']m䭮9{n\ă9yD+oHBRrk'2if5toִ'gv-:\*RRЁuGm] lq!Tmj%4_){{/Z2a8ǒ֝^.lrܼ15ugy̎dvkMk'5}Pצg) zfI#*L :Smz7x=[r"l6WU 툤Jys/'*4{.Z4'!ӻݑغ/wd*M/:cq̎́jh>8 ˟l+%tgGKC;cRQ{E'—7W5h#v-ұ1:61y# 59g)Iׄ<_`[MM7QS0 [ra~ߠYxڨ7_z0'vTMjM^қY+ ~2;]uʃ~)?5fޮ'8 C'wt?5@%_*2k~=;nN:8Knr,+ɇl=l\ySRIn}F77l~Xc4mqj;܍#va.ϊkWnlZ:onvˎ/^}]7}}x=ZGX.ؘPS܃JYr٧z{1~$?%dnK!Z3Lܰ o(N!g٣IhԌu< zdqm 4?tQ9JλD}=zϾ,~8bT~Cg,Z`Ϻ&ޅd^)UP(nYŠ}k/ov(o#W O>OqnJBEwMK|{&ut nk3lOxy3v'w6/kܕ|]g,Gez݂u ,>=9I$BHRj^Y/d-ȥ;%P%Z@u[?lӨ0lC- }tvZ;L @c+A~! ^x * ہ|(/dTضzG_޾& Qj@9N9f8+=u&rQ,0u>ſR[803xL/Bqwɘ^\`$LEl"PDOb LjF3Dk[D#aX(M 9w= `GV a(`|!PRca03=~`C@Z !ب@$a@*jqDBwV ك,\$4h`T1qa;%hF `RA]R"!΢`P>W"Bg^glg!Z^|^A9q"!8 %p&B%D-0E1GhC?C N,Mx G+SgfJ^ZOC{Dk(%֣KFТ ہr!P,H 0L ʁB-#*ECX .l.tV/@O0T?( ПPk8 `"Xd @qT 4!{_> ӆTB#"ah¶>џ5@fà:6y(_2/)"MGXZLK6 *_)AVwLeR7W.t& [mA)@GŮ)x[߫{o=vdD!c7~^]7ż~>v2lOeu2l n-{_~M0t 9_8Li g1[WLЌW E?+QF2c_9t7_T-9ֿd~UtslYnÿV_6n}8DQ~W# "*9re}ဏD T<ɂB ')*-kO$-C̴7MĐBP[MA]08"]Ye( ݧ3ȝH7;2 Zd xZ"!( ^)J5ppq3 q*8q Q 7Y0> v S`z0Pi: } =ɀu.ѝ,Kw'IЄi<_CJvT:p4^i)S2_X;_6ye]z=g" BlY[&1FF5nZcC!M'ڊciH$TU:T:4TT\5\T2jOEAdU*Y@ GeyH qb-v7aK)0ziݴnĐc0i y?0qIi9FF$1\z q-؋Wb~ |lT}>v2, ,'Mb'~ $qYDq0f3\D5pE(L Ҥj>xT M$y1|T2 sqj3YCNM&tH̶ 0v cn` U** ~C嫚LAI tM/84s&|2Yb<0hx2wِ`G*+)+o @ ^ &&Џ=R3X @V<Ab;*`8WK$w`f*-= \!ih 0 $c%?xlX^+ KJ `^ ϟͦch|MH= b>~R2[ę` @W:Pp0 5 03M ВFha.ԈR'@Ba#a/Q/M@<gZ8B8/`@_=?Md2(L2=ZZFVQ6^=oi z8$oyrA\q L;Ԓ)`א$[g V**Y,\Vba;[>>=ρa^#w1xBs2_4`.^>[Irx00OKӎi'֢[zb `Ebޛ:V&n`4y ̦u_0˂{u>~l6ǁsȬ>k mgqгJnpoT D e ~O;н]c߷L`vYcz{o[3SKS,_[٧6Y^htkv ܊%d2\~Zր>fSS%}aIFݿZQYIzIۍ3Y< ^#G;cG):L$b_z~/zOhgef2o |[7?Ausg5qcG㨧 {C6ek^,&׊yt\{d|²`.hx~'{WC?kôdUC^S5\S,;frQ-;mŒdXn,mfy?[3Xq,p$SqԏտZMZiF4w6[3*z=T_ےUFC1Pp8,>NIp|'"a-a^Ize"E 4$Ibyrf|g|]_ Jb;Ym,6Iߙk񡝦#f`2BrF[; jG{niS\kVK99iZsBɎ$$#hv69Y3n']Z#d1 8C1Ivk'roifB8mh[űbU\-[(+#"]frcvryhV,ۈ[4vNR #èbrgK2(o Z}:hao"@_=އ,v9Z+j2)7bS3e.RUz`-dxp!YǶdJuY]:M~.~agdR,Am sk)6]hD0ɲbY1_Wp|$|VbPG= lF_@QNqcs>LIyLsf2L&|!wrMVp٢d=1GwV2\= 'WQ2$#͐0Dѵ3m#63akW }bEsЊktP6"\I6h4 zpXfq s-t%c9hS`uV]ќhv@}aźy) ,uvg|f|.g*f1- 0:~U(/ɍ*Uphr&Jhǐ=^}Zc%$}F G5|g0lA], ]MlEhT8Pۤ(pʮ3fK qCV"?H$鏀n#A~(hZ@jGizYY{(zz4ٿ7f޼y{cg'l>O nu1{S"|T|+x'ts9XW>mCg1?2[R*o(SC ᜠE`}m-#2N^u@[ZGŢ⍰'ƙ2ZcW vzу1lppwZ+>c9uR9 Hуy٫ =;<^*3B1 f= Bu1~_VSBy#+9 ѮOuecXvy+kesYkfAHz- [1;y>>vx9 +@ԇr*P{"E?5 i)UNfOk29k`tiPә=54T*#qDs{NJoK'VIϪP/ ޛNh <&UNFr D͘;fU@F$2-};QGqI/0NRMhZ<at(DسzJzyd+|K j&`{ޓPQ!G)ڇx80_V4嵚wKdr!ѣ Q]$uMͲSOt"@}W_FUO {+zyLr#>7R$OS֞77;eoy\YnjmYQu/2#F̏=,ƙI`7Q>U4Zvr>' +{Vѝ،@ˊdž4aꑽMhKQܨg>UW[-Uƥ i͘OxBxv.>*/;?K>1{av1ka?2q7nУ5#,Y>&Cx¤:i+]9B?qoYn > }`=UF#Gg tHpicJ=0G !u-{J1&!j.m*ƊdX[(E'v[_Wk 7D:H]ܞJ|Hfqv,@iio,ـUc$7}jMG}x,};fVh1֯CLI== iE!X}@oR*TM;.ռڄ<fjbEa)qQ$ۿHiq-YU<`? K%nigmj-}CcfL}gAooYoKq%d hFne? (&g5{^ 6eVtW. /p 4s#ۀ ?H"7#,kݖF#ӧl$$If!vh5 5p5'5T5T#v #vp#v'#vT:V 4 6`>#,5 5p5'5T/  4f4g$$If!vh5 58585'5T5T#v #v8#v'#vT:V 4 6`<>#,5 585'5T/ /  / 4f4p<$$If!vh5 5p5'5T5T#v #vp#v'#vT:V 4 6`>#,5 5p5'5T/ 4f4Y$$If!vh5 58585'5T5T#v #v8#v'#vT:V 4 6`<>#,5 585'5T/ / 4f4p<$$If!vh5 5p5'5T5T#v #vp#v'#vT:V 4 6`>#,,5 5p5'5T/  / 4f4$$If!vh5 5p5'5T5T#v #vp#v'#vT:V 4 6`>#,5 5p5'5T/ 4f4$$If!vh55 55& #v5 #v#v& :V P40,55 55& 44 Paf4$$If!vh55 55& #v5 #v#v& :V P4055 55& 44 Paf4$$If!vh55 55& #v5 #v#v& :V P4055 55& 44 Paf4$$If!vh55 55& #v5 #v#v& :V P4055 55& 44 Paf4$$If!vh555x5505#v#v#vx#v#v0#v:V P4$,,555x5505/  / 44 Paf4$$If!vh555x5505#v#v#vx#v#v0#v:V P4$,555x5505/ 44 Paf4$$If!vh55j 55 #v#vj #v#v :V P4!,55j 55 / /  / 44 Paf4 $$If!vh55j 55 #v#vj #v#v :V P4!55j 55 / / / / / / / / 44 Paf4DyK ^http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-2/b/update_200805/ctd_05-2008.pdfyK http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-2/b/update_200805/ctd_05-2008.pdf"0@@@ NormalCJ_HaJmH sH tH H@H  Heading 1$$@&a$5CJ,\aJ,B@B  Heading 2$$@&a$CJ$aJ$L@L  Heading 3$&@#$/@&5\H@H  Heading 4$$@&a$5CJ\aJDA@D Default Paragraph FontVi@V  Table Normal :V 44 la (k(No List ZC@Z Body Text Indent$hA$]^ha$_H,6U@6 Hyperlink >*B*ph4@4 Header  9r 4 @"4 0Footer  9r .)@1. Page NumberjCj l Table Grid7:V0V^@RV E\ Normal (Web)dd[$\$CJOJQJ^JaJVObV HkDefault 7$8$H$!B*CJ_HaJmH phsH tH 6Oq6 )q0 Char Char3CJaJO hps2O2  gt-icon-text1TOT |TJTablas$da$ CJOJQJ^JaJmH sH tH P+@P t5 Endnote TextCJOJQJaJmH sH tH BOB t5 Char Char2OJQJmH sH tH <P@< C Body Text 2 dx6O6 C Char Char1CJaJ@O@ l List Paragraph ^2B@2 !b Body Text x4O4 b Char CharCJaJFF "& "& "& "& "& "& "& "& "& "& "& "& "& "& "& "& "& "& "& "& "& "& "& "&  m#,3:.AAE+KQX`hVnSvz|.QFw     ' CDEFt89@|    89g78ToNtU {  d sj <71Ciefg% ` a !!""k#l#m#n##%n(o((*+--).//>/00011=2s22223A4B4C4`444u6777 8 999:::-;k;;h<u<o=p====>(>_>>>> ?r?s??L@z@@@@-A.A/AwAABBBB[BBBB-CZC[CCD[DD8E9E:E;EE?E@EAEBECEEEERFMGbGpGqGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGDH!I"II J+K,K-K}K L!LLLsMtMMMM\NOOOPPP#QSSStST%UBUUUUcVdVVVWWWXXYzYZZ9[\\] ^^^^8`9``````;aqaab}bbcIc ddd6eeFffffCgggggh h h h h hhhhhhhhhhhhzhhhhIii8jk5k6k7kkk8lllllllllmmm'mm?m@mAmBmCmDmEm`mrmsmmmmmmmmmmmmmmmmmTnUnVnWnnuovopjpkppqqqpqq4r5rzrrrLsMssttzu{uuuSvTvUvvNw3xcxdxexxx@yyzzzzwzxzyzzz{z|z}z~zzzzzzzzzzzzzzzi{{{{{{{ | |]|^||||||||||||||||||||||||||||||'}T}U}q}r}}}}}}}~~~~~(>bcPԀ-./01ú΁EFԂՂ$]^ɃC QRSTUVWׇ݈ވ @G*$ *$ *$*$ *$ *$ *$ *$ *$ *$ *$ *$ *$ *$t*$t*$t*$t*$t*$Y*$Y*$Y*$Y*$*$*$*$*$ X*$O *$ X*$4 *$Y*$Y*$Y*$4 *$Y*$Y*$Y*$Y*$Y*$s*$>*$>*$VD*$O *$Y*$Y*$Y*$Y*$*$*$*$*$*$*$Y*$*$ *$*$*$3*$*$*$*$ڜ*$[ *$ܷ*$Y*$*$[ *$*$*$*$*$*$*$[ *$*$ܷ*$[ *$[ *$*$*$*$ܷ*$*$Y*$e*$*$[ *$*$[ *$*$*$B*$*$*$*$*$*$E+*$ *$ *$*$ *$*$*$e*$^*$^*$^*$^*$*$*$q*$,*$R *$q*$R *$*$*$*$*$,*$q*$q*$*$Y*$*$Y*$q*$R *$q*$q*$q*$q*$I *$I *$q*$q*$*$Y*$*$q*$R *$Y*$q*$q*$*$q*$q*$Y*$q*$q*$q*$q*$q*$*$ܷ*$,*$q*$q*$q*$,*$q*$*$*$q*$q*$q*$Y*$q*$R *$Y*$q*$q*$*$q*$,*$,*$q*$Y*$*$*$*$q*$[ *$q*$q*$q*$q*$q*$q*$,*$q*$q*$R *$q*$q*$q*$q*$q*$q*$q*$q*$q*$q*$q*$q*$q*$[ *$[ *$*$*$[ *$*$*$*$,*$,*$,*$,*$q*$q*$q*$q*$q*$q*$*$*$*$*$*$J3*$q*$,*$,*$Y v:av:av:v:Ev:Ev:Ev:Ev: PS8PS8PS'PSTPSMPSPS PSaPSPSEPSEPSPS PS8PS8PS'PSTPSMPSPS PSaPSPSEPSEPSPS PSfPSPSJPSJPSPS*$q*$,*$Y*$q*$,*$,*$3*$q*$q*$q*$R *$q*$,*$,*$,*$q*$q*$q*$q*$,*$3*$q*$,*$q*$R *$q*$,*$*$q*$q*$,*$3*$,*$q*$,*$q*$q*$,*$q*$q*$,*$Y*$q*$,*$R *$q*$,*$,*$,*$R *$,*$3*$q*$,*$Y*$,*$*$*$*$*$,*$q*$q*$q*$q*$q*$q*$q*$,*$,*$q*$,*$q*$R *$,*$q*$,*$,*$,*$q*$,*$*$*$*$  Y v:v: v:u: v:v: v:u: v:v: v:u:*$*$*$*$*$*$*$*$*$*$*$s*$*$s*$s*$s*$q*$q*$,*$qjjjjjjhjjjjjPSPSPSPShPSPSPS*$jjjjjjhjhj/ j/ jPSPSPShj/ j*$*$ *$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$( *$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$a*$*$ *$*$*$*$*$*$*$I=*$*$*$*$*$*$*$v:*$v:*$v:*$v:*$v:*$v:*$v:*$v:*$v:*$v:*$v:*$v:*$v:*$v:*$v:*$v:*$v:*$v:*$v:*$v:*$v:*$v:*$t*$Y*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$*$v:*$*$ CDEFt89@|    89g+78ToNtU {  d sj <71Ciefg% ` a !!""k#l#m#n##%n(o((*+--).//>/00011=2s22223A4B4C4`444u6777 8 999:::-;k;;h<u<o=p====>(>_>>>> ?r?s??L@z@@@@-A.A/AwAABBBB[BBBB-CZC[CCD[DD8E9E:E;EE?E@EAEBECEEEERFMGbGpGqGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGDH!I"II J+K,K-K}K L!LLLsMtMMMM\NOOOPPP#QSSStST%UBUUUUcVdVVVWWWXXYzYZZ9[\\] ^^^^8`9``````;aqaab}bbcIc ddd6eeFffffCgggggh h h h h hhhhhhhhhhhhzhhhhIii8jk5k6k7k8kkkk8lllllllllmmm'mm?m@mAmBmCmDmEm`mrmsmmmmmmmmmmmmmmmmmTnUnVnWnnuovopjpkppqqqpqq4r5rzrrrLsMssttzu{uuuSvTvUvvNw3xcxdxexxx@yyzzzzwzxzyzzz{z|z}z~zzzzzzzzzzzzzzzi{{{{{{{ | |]|^||||||||||||||||||||||||||||||'}T}U}q}r}}}}}}}~~~~~(>bcPԀ-./01ú΁EFԂՂ$]^ɃC QRSTUVWׇ݈ވ߈ @ABCDG000000000000000000000000000000000000000000 0 0 0 00 0 00000 00 000 0 0 0 0 0 00000 000 00 00 0 00 0 0000 000 00 0 0 0 000 000000 0 000 0000000000000000000000000000000000000000000000000 0 0 000000000000000000000000000000000000000000000000000000000000000000000000000000000000000 0 000 00 0 0 0 0 0 00 0 0 0 0 00 0 0 0 0 0 00 0 0 0 0 00 0 0 0 0 00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000 0 0 00 0 0 00 0 0 0000000000 00 000000000000 000 0 0 00 00 00 00 0 0 0 0 000000 00 00 00 000 0 0 0 0000000000000000000000000000800t0t0t0t0t0t0t0t 0t 0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t 0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t 0t0t0t0t0t0t0t0t 0t0t 0r}t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t 0t0t0t0t 0t0t0t0t 0t0t0t0t 0t0t0t0t 0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t0t 0t 0t 0t 0t 0t0tHI00I00I00I00I00I00I00I000I00I00I00I0000I00I00I00I00 6Acccft7 ? B ]eAoe "#Q&E'()+g/9}=BADFHIKLNPQSUVYa] _aSh,kn/pOqrptuwByz}\хeW%ILNOQRTUVXY[\^_abdefhijlmnpqsuwxz{} 8 Yv &*39;?FHJLxNPPPPPP Q QQQQQeT0WY\aimBqFqJqNqr)uavzvvvwx|5jJMPSWZ]`cgkortvy|~K)5QFXX6=AY_f!!  ?2$L&)8$b$Qo-ŷ s@ (  P   3 "?B S  ?   F G"GrTwwD[lvlQê! !|  E BB~EbGmG     H BBEfGmG B*urn:schemas-microsoft-com:office:smarttagscountry-region8 *urn:schemas-microsoft-com:office:smarttagsCity9 *urn:schemas-microsoft-com:office:smarttagsplace? *urn:schemas-microsoft-com:office:smarttags stockticker Tb   s""66>>@@AANNUU[[uaac+cQc[c\cfcddddddiipjzj~~~~~~cjnsw|߈CGKQ NZ w z %015jnd j 5(m(o--/ 00022F4L46677::0;6;;;s=y===5>;>>>>>v?|?@@G€Ҁej 58Q\cl,4߈CG:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: | 9h9o ' j <1Cn##5(n(o((0011C4`4p==2>_>MGoGqGGGGUUghk4kllm'mEmmmmmmmmzzi{{{{{{ |||||U}}~Ԃ߈CG߈CG4^od ~;BEh6a ]\}HJF#5#XlGJ#,YK;?$P4H]$G؅`&;A&2]\'"0\0N1p0J2|;1282F2k{@0  #@4WHJj/{-YZd%\X0kdJTk @Ul`l֛xNcpJnlPq* ^` CJo( ^` CJo(.0^`0CJo(..0^`0CJo(... 0^`0CJo( .... 8^8`CJo( ..... 8^8`CJo( ...... `^``CJo(....... `^``CJo(........h h^h`B*o(ph-h ^`hH.h L^`LhH.h  ^ `hH.h R^R`hH.h "L^"`LhH.h ^`hH.h ^`hH.h L^`LhH.  ]^`.hhhhhhhh ]^`OJPJQJ^Jo(- ]^`OJQJo(o ppp]p^p`OJQJo( @ @ @ ]@ ^@ `OJQJo( ]^`OJQJo(o ]^`OJQJo( ]^`OJQJo( ]^`OJQJo(o PPP]P^P`OJQJo(h^h`CJOJPJQJ^Jo(-8^8`OJQJ^Jo(hHo^`OJQJo(hH ^ `OJQJo(hH ^ `OJQJ^Jo(hHox^x`OJQJo(hHH^H`OJQJo(hH^`OJQJ^Jo(hHo^`OJQJo(hHh^h`OJPJQJ^Jo(-^`OJQJ^Jo(hHo^`OJQJo(hH^`OJQJo(hH ^ `OJQJ^Jo(hHo\^\`OJQJo(hH,^,`OJQJo(hH^`OJQJ^Jo(hHo^`OJQJo(hHh^`OJQJo(hH ^`hH. pp^p`hH. @ @ ^@ `hH. ^`hH. ^`hH. ^`hH. ^`hH. PP^P`hH.hpp^p`OJQJo(hHh@ @ ^@ `OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHhPP^P`OJQJo(hHh  ^ `OJQJ^Jo(hHoh^`OJQJo(hH ]^`OJPJQJ^Jo(- ]^`OJQJo(o ppp]p^p`OJQJo( @ @ @ ]@ ^@ `OJQJo( ]^`OJQJo(o ]^`OJQJo( ]^`OJQJo( ]^`OJQJo(o PPP]P^P`OJQJo(0^`0o(0^`0o(.0^`0o(..0^`0o(... 0^`0o( .... 88^8`o( ..... 88^8`o( ...... `^``o(....... `^``o(........hh^h`OJQJo(hH^`OJQJ^Jo(hHo^`OJQJo(hH^`OJQJo(hH ^ `OJQJ^Jo(hHo\^\`OJQJo(hH,^,`OJQJo(hH^`OJQJ^Jo(hHo^`OJQJo(hH h^h`5\o(- ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH.h^h`o(-^`OJQJ^Jo(hHo^`OJQJo(hH^`OJQJo(hH ^ `OJQJ^Jo(hHo\^\`OJQJo(hH,^,`OJQJo(hH^`OJQJ^Jo(hHo^`OJQJo(hHhh^h`CJ$OJQJaJ$o(hHht^t`OJQJ^Jo(hHohD^D`OJQJo(hHh ^ `OJQJo(hHh ^ `OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHhT^T`OJQJ^Jo(hHoh$^$`OJQJo(hHh^h`OJPJQJ^Jo(-8^8`OJQJ^Jo(hHo^`OJQJo(hH ^ `OJQJo(hH ^ `OJQJ^Jo(hHox^x`OJQJo(hHH^H`OJQJo(hH^`OJQJ^Jo(hHo^`OJQJo(hHh^h`o(- 8^8`hH. L^`LhH.  ^ `hH.  ^ `hH. xL^x`LhH. H^H`hH. ^`hH. L^`LhH.-^-`o(- ^`hH.  L^ `LhH.  ^ `hH. m^m`hH. =L^=`LhH.  ^ `hH. ^`hH. L^`LhH. ]^`OJPJQJ^Jo(- ]^`OJQJo(o ppp]p^p`OJQJo( @ @ @ ]@ ^@ `OJQJo( ]^`OJQJo(o ]^`OJQJo( ]^`OJQJo( ]^`OJQJo(o PPP]P^P`OJQJo( ]^`OJPJQJ^Jo(- ]^`OJQJo(o ppp]p^p`OJQJo( @ @ @ ]@ ^@ `OJQJo( ]^`OJQJo(o ]^`OJQJo( ]^`OJQJo( ]^`OJQJo(o PPP]P^P`OJQJo(h^h`o(- 8^8`hH. L^`LhH.  ^ `hH.  ^ `hH. xL^x`LhH. H^H`hH. ^`hH. L^`LhH.hh^h`OJQJo(hH^`OJQJ^Jo(hHo^`OJQJo(hH^`OJQJo(hH ^ `OJQJ^Jo(hHo\^\`OJQJo(hH,^,`OJQJo(hH^`OJQJ^Jo(hHo^`OJQJo(hH 0]^`0o( @ 0@ ]^@ `0o(. 0]^`0o(.. 888]8^8`o(...  `]^``o( ....  `]^``o( .....  ]^`o( ......  ppp]p^p`o(.......  ppp]p^p`o(........^`OJPJQJ^Jo(-^`OJQJ^Jo(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJQJo(hH^`OJQJo(hH^`OJQJ^Jo(hHoPP^P`OJQJo(hH ^`hH. ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH.h hh^h`hH.h^h`o(- 8^8`hH. L^`LhH.  ^ `hH.  ^ `hH. xL^x`LhH. H^H`hH. ^`hH. L^`LhH.^`o(. ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH. ]^`OJPJQJ^Jo( ]^`OJQJo(o ppp]p^p`OJQJo( @ @ @ ]@ ^@ `OJQJo( ]^`OJQJo(o ]^`OJQJo( ]^`OJQJo( ]^`OJQJo(o PPP]P^P`OJQJo(BEBEM 6a2k{@PqGJ#2{-YxNcpd%\#5#K;?$4\'TkHJ]`&Ul`l #@;120N1J20kd;A&od WHJH]$bz        .^txh2        c:                 ,         2         }        @                N                        C6Hm@                 b                   ʝ                 J4L*?w+XNf7"] XNf7"E[4#XNf:|%XNf?w+M0:|%&GHDL*ySNOR^ gR:|%h:-SE[&GHDORXNf'&)! 9|bbh?R rQmvj^x }9J Uj, iI Y Zi v  5 N m ( w ~ ,K P l\ 0e  Ar (D /%3%HHEap0z_t! +/ F@S\k3"/eQ,\acn.dI@Hky0:AS+{s/E]k#ejnM~  1Jq' -+ ` !!!>!PG!T!w!A"X"h"-#$.$E$`$|e$7l$%6%q%y%F &?&@&_&\c&ku&j'/'Z']V(**x++--+:+ ,,l6,T,i,-9-XQ-.%.+.y.i/Y/[/z/ /%0,0dR02E2k2{2"3nB3B3I4h4s4U45et5t5^77H7V7gJ8~8 9<::;\;d;Lm;y;<<6<i<Y=a=\g=yr==h >:>+M>;)?+?@@X@\@A.AA#AJAPAHaAi)C.LCBUCV!D$D 0D EVbE3FFF8RF`FxFPG+GYyG_ HBCH^rHSIUIJJlJhOJ|TJBKkKnKGsKL)L M+3M@MAMJNrN{ OO7PP+P0P9[P&FQpQRw RR(RFRURXReRS@SFSYSgSxS T(TMT.PT`T U'USUyU6WYWrXX_(Xm.X+uXnZ^Z7[e<[=[uF[KY[il[q[s[Q6\E\\4]i^]^'$^i1^9^@^SL^ _+_L_`Z` s`3a]at b9#b+cL1c>cScQ&dwdjeoefC$f%f'fgfqgLh |hiU$iristi1jkEkHkMk l0Jlm m mUm` nInoooiZooo phPpop)qIqrxrrOrSr Yrvgrpr/ sshss)s -snQstltrt /u@uLau vvdv*/vJKv|v-w.waQw~`wSfw/lw}wx"x yHzzzAz,OzdzxzS{{o{< |2J|5~i,~5 ]dru2$+R%wj$]qwSAT{g;?FlV 7Yk4|]<FH]|%=4:2)A n{Dl'FQ6RVtZsLRkz1TbW=i\~18 uNRXk8\"~Pt?CUE6H6"v$"28v{z2~BXKcb3/0y,qKsmFJ->/Y/h3r5kj &m>^zg t50(T&SIl <$6s *R:=ATdXchkg +6 tzz78XR8 ;AQ  HH^jM CNE$c?Me1N: XdS )>+X=qI9]m!ldgn}>> LO)Yo(~3TV R\tj|oJ"Qxr(h/Tck*N ,4=kn:Di!EU 3$0B6<:@LP8`lntfu E MX$f^Kd@?HOY[A E3V4<AV{*[2`tru&~D6 LXxe ;q4}NY}s)WOKamtT3mt| COQVC_[\|"R(J=+1YdlJ^~"9yi4/F1^LRux}-c5I^v4[p A1i~v^mnu#t<%0Fi,:vDzb,O-&(EmY`52`>FiOzmSvv{NXRbsk#sRFMGbGqGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGggggh h h h h hhhhhhhhh8llllllmmm@mAmBmCmDmEm`mmmmmmmmmmmGQ5Q5@ M4FP@PP @P0@Unknown Gz Times New Roman5Symbol3& z Arial7.@ CalibricTimesNewRomanTimes New RomanM @TimesNewRoman,Bold9New York?5 z Courier New;Wingdings"phQ[:&:&mrtEmrtE!>4d 3qHX(?K2PART IICwesal wesal.haqaish|                       Oh+'0   @ L X dpx PART IICwesal Normal.dotwesal.haqaish541Microsoft Office Word@4 !@<;@YdJ@mrt՜.+,D՜.+,4 hp|  E  PART IIC Title 8@ _PID_HLINKSAP m`^http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-2/b/update_200805/ctd_05-2008.pdf=dhttp://www.jfda.jo/  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry FJNData 1TableJBWordDocumentSummaryInformation(DocumentSummaryInformation8CompObjq  FMicrosoft Office Word Document MSWordDocWord.Document.89qRoot Entry FPLhVData 1TableJBWordDocument՜.+,D՜.+,4 hp|  E  PART IIC Title 8@ _PID_HLINKSAP m`^http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-2/b/update_200805/ctd_05-2008.pdf=dhttp://www.jfda.jo/SummaryInformation(DocumentSummaryInformation8CompObjq